<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Genet</journal-id><journal-id journal-id-type="iso-abbrev">Hum Genet</journal-id><journal-title-group><journal-title>Human Genetics</journal-title></journal-title-group><issn pub-type="ppub">0340-6717</issn><issn pub-type="epub">1432-1203</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38459354</article-id><article-id pub-id-type="pmc">11043200</article-id>
<article-id pub-id-type="publisher-id">2649</article-id><article-id pub-id-type="doi">10.1007/s00439-024-02649-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title><italic>PKHD1L1</italic>, a gene involved in the stereocilia coat, causes autosomal recessive nonsyndromic hearing loss</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3485-6654</contrib-id><name><surname>Redfield</surname><given-names>Shelby E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2434-3345</contrib-id><name><surname>De-la-Torre</surname><given-names>Pedro</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7005-3787</contrib-id><name><surname>Zamani</surname><given-names>Mina</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Hanjun</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Hina</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Morris</surname><given-names>Tyler</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shariati</surname><given-names>Gholamreza</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Karimi</surname><given-names>Majid</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0851-9272</contrib-id><name><surname>Kenna</surname><given-names>Margaret A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Seo</surname><given-names>Go Hun</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Hongen</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1912-0235</contrib-id><name><surname>Naz</surname><given-names>Sadaf</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Galehdari</surname><given-names>Hamid</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2076-6818</contrib-id><name><surname>Indzhykulian</surname><given-names>Artur A.</given-names></name><address><email>Artur_Indzhykulian@hms.harvard.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5324-4805</contrib-id><name><surname>Shearer</surname><given-names>A. Eliot</given-names></name><address><email>Eliot.Shearer@childrens.harvard.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6719-3447</contrib-id><name><surname>Vona</surname><given-names>Barbara</given-names></name><address><email>barbara.vona@med.uni-goettingen.de</email></address><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00dvg7y05</institution-id><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution>Department of Otolaryngology and Communication Enhancement, </institution><institution>Boston Children&#x2019;s Hospital, </institution></institution-wrap>300 Longwood Avenue, BCH-3129, Boston, MA 02115 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04g3dn724</institution-id><institution-id institution-id-type="GRID">grid.39479.30</institution-id><institution-id institution-id-type="ISNI">0000 0000 8800 3003</institution-id><institution>Mass Eye and Ear, </institution><institution>Eaton Peabody Laboratories, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Department of Otolaryngology Head and Neck Surgery, </institution><institution>Harvard Medical School, </institution></institution-wrap>25 Shattuck Street, Boston, MA 02115 USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01k3mbs15</institution-id><institution-id institution-id-type="GRID">grid.412504.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0612 5699</institution-id><institution>Department of Biology, Faculty of Science, </institution><institution>Shahid Chamran University of Ahvaz, </institution></institution-wrap>Ahvaz, Iran </aff><aff id="Aff5"><label>5</label>Narges Medical Genetics and Prenatal Diagnosis Laboratory, Kianpars, Ahvaz, Iran </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ypx8c21</institution-id><institution-id institution-id-type="GRID">grid.207374.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2189 3846</institution-id><institution>Precision Medicine Center, Academy of Medical Science, </institution><institution>Zhengzhou University, </institution></institution-wrap>No. 40 Daxuebei Road, Zhengzhou, 450052 China </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/011maz450</institution-id><institution-id institution-id-type="GRID">grid.11173.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 0670 519X</institution-id><institution>School of Biological Sciences, </institution><institution>University of the Punjab, </institution></institution-wrap>Quaid-e-Azam Campus, Lahore, 54590 Pakistan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01rws6r75</institution-id><institution-id institution-id-type="GRID">grid.411230.5</institution-id><institution-id institution-id-type="ISNI">0000 0000 9296 6873</institution-id><institution>Department of Medical Genetics, Faculty of Medicine, </institution><institution>Ahvaz Jundishapur University of Medical Sciences, </institution></institution-wrap>Ahvaz, Iran </aff><aff id="Aff9"><label>9</label>Khuzestan Cochlear Implantation Center (Tabassom), Ahvaz, Iran </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.520015.3</institution-id><institution>3Billion, Inc., </institution></institution-wrap>Seoul, South Korea </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/056swr059</institution-id><institution-id institution-id-type="GRID">grid.412633.1</institution-id><institution>Department of Otorhinolaryngology, </institution><institution>The First Affiliated Hospital of Zhengzhou University, </institution></institution-wrap>No. 1 Jian-She Road, Zhengzhou, 450052 China </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/021ft0n22</institution-id><institution-id institution-id-type="GRID">grid.411984.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0482 5331</institution-id><institution>Institute of Human Genetics, </institution><institution>University Medical Center G&#xF6;ttingen, </institution></institution-wrap>37073 G&#xF6;ttingen, Germany </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/021ft0n22</institution-id><institution-id institution-id-type="GRID">grid.411984.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0482 5331</institution-id><institution>Institute for Auditory Neuroscience and InnerEarLab, </institution><institution>University Medical Center G&#xF6;ttingen, </institution></institution-wrap>37075 G&#xF6;ttingen, Germany </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2024</year></pub-date><volume>143</volume><issue>3</issue><fpage>311</fpage><lpage>329</lpage><history><date date-type="received"><day>9</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2024</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2024</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Identification of genes associated with nonsyndromic hearing loss is a crucial endeavor given the substantial number of individuals who remain without a diagnosis after even the most advanced genetic testing. <italic>PKHD1L1</italic> was established as necessary for the formation of the cochlear hair-cell stereociliary coat and causes hearing loss in mice and zebrafish when mutated. We sought to determine if biallelic variants in <italic>PKHD1L1</italic> also cause hearing loss in humans. Exome sequencing was performed on DNA of four families segregating autosomal recessive nonsyndromic sensorineural hearing loss. Compound heterozygous p.[(Gly129Ser)];p.[(Gly1314Val)] and p.[(Gly605Arg)];p[(Leu2818TyrfsTer5)], homozygous missense p.(His2479Gln) and nonsense p.(Arg3381Ter) variants were identified in <italic>PKHD1L1</italic> that were predicted to be damaging using in silico pathogenicity prediction methods. In vitro functional analysis of two missense variants was performed using purified recombinant PKHD1L1 protein fragments. We then evaluated protein thermodynamic stability with and without the missense variants found in one of the families and performed a minigene splicing assay for another variant. In silico molecular modeling using AlphaFold2 and protein sequence alignment analysis were carried out to further explore potential variant effects on structure. In vitro functional assessment indicated that both engineered PKHD1L1 p.(Gly129Ser) and p.(Gly1314Val) mutant constructs significantly reduced the folding and structural stabilities of the expressed protein fragments, providing further evidence to support pathogenicity of these variants. Minigene assay of the c.1813G&gt;A p.(Gly605Arg) variant, located at the boundary of exon 17, revealed exon skipping leading to an in-frame deletion of 48 amino acids. In silico molecular modeling exposed key structural features that might suggest PKHD1L1 protein destabilization. Multiple lines of evidence collectively associate <italic>PKHD1L1</italic> with nonsyndromic mild&#x2013;moderate to severe sensorineural hearing loss. <italic>PKHD1L1</italic> testing in individuals with mild&#x2013;moderate hearing loss may identify further affected families.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00439-024-02649-2.</p></sec></abstract><funding-group><award-group><funding-source><institution>De Garay Family Fund</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Boston Children&#x2019;s Rare Disease Cohort Initiative</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008696</institution-id><institution>University of the Punjab</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000055</institution-id><institution>National Institute on Deafness and Other Communication Disorders</institution></institution-wrap></funding-source><award-id>R01DC017166</award-id><award-id>K08 DC019716</award-id><principal-award-recipient><name><surname>Lu</surname><given-names>Wei</given-names></name><name><surname>Naz</surname><given-names>Sadaf</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>VO 2138/7-1 grant 469177153</award-id><principal-award-recipient><name><surname>Galehdari</surname><given-names>Hamid</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Herzzentrum G&#xF6;ttingen (1018)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#xA9; Springer-Verlag GmbH Germany, part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par2">Hearing&#xA0;loss-associated genes are implicated in the function of all parts of the delicate molecular machinery that permits human hearing. The inner hair cells (IHCs) and outer hair cells (OHCs) of the organ of Corti contain an apical bundle of&#x2009;~&#x2009;100 actin-filled protrusions called stereocilia. Upon sound stimulation, stereocilia bundles are deflected by pressure-induced waves within the fluid-filled organ of Corti. Housing the mechanotransduction apparatus at the tips of stereocilia, these bundles mediate the transformation of the mechanical stimulus into an electrical signal the brain interprets as sound. While IHCs convert sound waves into nerve signals, OHCs allow for non-linear amplification of the sound stimuli by changing their length in response to bundle deflection, a process known as electromotility (Brownell <xref ref-type="bibr" rid="CR3">1990</xref>). Although IHCs and OHCs have two separate and distinct functions, both sensory cell types require a properly organized, functional stereocilia bundle. Stereocilia have a transiently expressed surface coat that was first observed in the 1980s as an electron dense material (Santi and Anderson <xref ref-type="bibr" rid="CR46">1987</xref>; Slepecky and Chamberlain <xref ref-type="bibr" rid="CR51">1985</xref>), but little is understood about the function or molecular architecture of this surface specialization. To date, there are over 30 genes reported to be critical for stereocilia bundle morphology that are associated with sensorineural hearing loss (SNHL) in humans (Michalski and Petit <xref ref-type="bibr" rid="CR32">2015</xref>; Petit and Richardson <xref ref-type="bibr" rid="CR39">2009</xref>).</p>
      <p id="Par3">One such stereocilia protein, polycystic kidney and hepatic disease 1-like 1 (PKHD1L1), also called fibrocystin-L, is critical for hearing in mice (Wu et al. <xref ref-type="bibr" rid="CR58">2019</xref>). The <italic>PKHD1L1</italic> gene in humans encodes a 4,243 amino acid protein, which is predicted to be composed by a large extracellular domain, a 20 amino acid transmembrane domain, and a very short cytoplasmic domain of 8 residues. In mice, PKHD1L1 is highly enriched in both IHCs and OHCs, particularly at the tips of OHC stereocilia bundles (Wu et al. <xref ref-type="bibr" rid="CR58">2019</xref>). It is hypothesized that this protein makes up the majority of the transient stereocilia coat observed on the surface of hair-cell stereocilia membrane. Mice lacking <italic>Pkhd1l1</italic> displayed elevated auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) thresholds in response to pure-tone stimuli in a progressive fashion (Wu et al. <xref ref-type="bibr" rid="CR58">2019</xref>), and lacked the stereocilia coat. More recent data from zebrafish (<italic>Danio rerio, Dr</italic>) with a double knockout of <italic>pkhd1l1a</italic> and <italic>pkhd1l1b</italic> (orthologs of human (<italic>Hs</italic>) <italic>PKHD1L1</italic>) show significant deficits in auditory startle responses at the larval stage, consistent with an early-onset auditory phenotype in zebrafish (Makrogkikas et al. <xref ref-type="bibr" rid="CR30">2023</xref>). Based on these findings in animal models, we sought to determine whether variants in <italic>PKHD1L1</italic> cause hearing loss in humans.</p>
      <p id="Par4">In this study, we propose defects of <italic>PKHD1L1</italic> as causal for autosomal recessive nonsyndromic hearing loss in humans. We describe four unrelated families with biallelic variants in <italic>PKHD1L1</italic> identified via exome sequencing. All four probands presented with&#xA0;bilateral congenital SNHL which is nonsyndromic and mild&#x2013;moderate to severe. In addition, in vitro functional evaluation of two missense variants in protein fragments shows decreased stabilities, suggesting that they may negatively impact their structures and molecular assembly in vitro, while a minigene assay of the c.1813G&gt;A variant reveals aberrant splicing.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Recruitment and clinical assessment</title>
        <p id="Par5">This study was approved by the institutional review boards of Boston Children&#x2019;s Hospital (IRB P-00031494), University Medical Center G&#xF6;ttingen (No. 3/2/16), the School of Biological Sciences, University of Punjab, Lahore, Pakistan (IRB No. 00005281), and the First Affiliated Hospital of Zhengzhou University (No. 2021-KY-0989). Written informed consent was obtained from participating members of the four families or parents for their minor children.</p>
        <p id="Par6">The proband in Family 1 was derived from non-consanguineous parents and was ascertained as part of a cohort of 389 pediatric patients with SNHL at Boston Children&#x2019;s Hospital in Boston, United States. This cohort mostly includes individuals who were born to non-consanguineous parents (only three probands with consanguinity reported). Any individual with SNHL was eligible for inclusion in the cohort regardless of SNHL laterality or severity, family history of SNHL, or presence of syndromic features. Two hundred forty-five probands had no prior genetic testing at the time of ascertainment, while one hundred forty-four probands had some previous non-diagnostic genetic testing (variable methodologies). The proband in Family 2 was derived from consanguineous parents who were first-degree cousins and was ascertained as part of a large ethnically diverse Iranian population rare disease study consisting of approximately 800 probands with the sole inclusion criteria being hereditary hearing impairment. The proband in Family 3 was born to consanguineous parents and identified from a special education school in Lahore, Pakistan. The parents did not participate in the study. This proband is part of a cohort of 62 individuals with moderate to severe hearing loss who were born to consanguineous parents with no previous history of deafness in their families. The proband in Family 4 was derived from non-consanguineous parents and sequenced as part of the Henan hearing loss cohort. This set comprises a total of 1450 hearing loss probands mainly from Henan Province, China, and it includes syndromic and nonsyndromic hearing loss. Most of the cohort was first tested by a lab-developed multiplex PCR kit covering the total coding sequencing of <italic>GJB2</italic>, <italic>SLC26A4</italic>, and <italic>MT-RNR1</italic> [described in a previous study (Zeng et al. <xref ref-type="bibr" rid="CR64">2022b</xref>)], as these are the most common causative genes in this population. If negative, exome sequencing was performed [the so-called step-wise approach as described previously (Zeng et al. <xref ref-type="bibr" rid="CR64">2022b</xref>)]. A fraction of patients chose exome sequencing as the first-tier test, while others with negative multiplex PCR were not tested by exome sequencing if DNA from both parents was not available. The proband in Family 4 was identified from a subset of 449 probands for whom exome sequencing data were available.</p>
        <p id="Par7">Demographic, otolaryngologic, audiological, and relevant medical data were ascertained from the medical records of probands. Affected individuals underwent a complete otologic evaluation. Routine pure-tone audiometry was performed according to current standards in all probands and measured hearing thresholds at 0.25, 0.5, 1, 2, 4, 6, and 8&#xA0;kHz. The probands in Families 1 and 2 underwent tympanometry and speech audiometry testing, while the proband in Family 4 underwent tympanometry. Probands 2 and 4 additionally underwent otoacoustic emissions testing. Pure-tone audiometry for proband 3 was performed in ambient noise conditions due to lack of soundproof testing environment.</p>
      </sec>
      <sec id="Sec4">
        <title>Exome sequencing</title>
        <p id="Par8">Genomic DNA (gDNA) from individuals in families 1 (I:1, I:2, and II:1), 2 (I:1, I:2, II:1, and II:2), 3 (II:1), and 4 (I:1, I:2, and II:1) was isolated from either buccal mucosa or whole blood using standard procedures.</p>
        <sec id="Sec5">
          <title>Family 1</title>
          <p id="Par9">Exome sequencing was performed in a Clinical Laboratory Improvements Amendments (CLIA)-certified environment (GeneDx, Gaithersburg, MD, USA). Analysis was performed using the DRAGEN pipeline (Illumina, San Diego, CA, USA). Copy number variants (CNVs) were called using the DRAGEN CNV pipeline and a normalized segmented depth of coverage model, as previously described (Rockowitz et al. <xref ref-type="bibr" rid="CR44">2020</xref>).</p>
        </sec>
        <sec id="Sec6">
          <title>Family 2</title>
          <p id="Par10">Exome sequencing was applied to the DNA sample of the proband by Macrogen. Briefly, the sample was subjected to exome enrichment with the SureSelect Target Enrichment v6 kit (Agilent Technologies, Santa Clara, CA, USA), followed by sequencing with Illumina NovaSeq 6000 (Illumina, San Diego, CA, USA) using standard protocols. Then short reads were aligned to the human genome reference version B38 using BWA and duplicate reads were marked using Picard. GATK and ANNOVAR were used for variant detection and annotation, respectively. Variant filtering and assessment was performed as previously described with slight modifications as described in the variant validation and assessment section (Vona et al. <xref ref-type="bibr" rid="CR55">2021</xref>). CNVs were called using a read-depth based in-house tool, including exomeCopy (Love et al. <xref ref-type="bibr" rid="CR29">2011</xref>) and exomeDepth R packages (Plagnol et al. <xref ref-type="bibr" rid="CR40">2012</xref>). CNVs were predicted using a model of the normalized read depth.</p>
        </sec>
        <sec id="Sec7">
          <title>Family 3</title>
          <p id="Par11">Exome sequencing for the proband was carried out at 3billion, Inc., Seoul, South Korea (<ext-link ext-link-type="uri" xlink:href="https://3billion.io/index">https://3billion.io/index</ext-link>). Briefly, coding exon regions of human genes (~&#x2009;22,000) were captured by xGen Exome Research Panel v2 (Integrated DNA Technologies, Coralville, IA, USA). The captured regions of the genome were sequenced with NovaSeq 6000 (Illumina, San Diego, CA, USA). The raw genome sequencing data analysis, including alignment to the GRCh37/hg19 human reference genome and variant calling and annotation, was conducted with an open-source bioinformatics tool Franklin (<ext-link ext-link-type="uri" xlink:href="https://franklin.genoox.com/clinical-db/home">https://franklin.genoox.com/clinical-db/home</ext-link>) as well as using 3billion in-house software. CNV calling from exome data, including for aneuploidy, was performed using CoNIFER v0.2.2 (Krumm et al. <xref ref-type="bibr" rid="CR24">2012</xref>) and 3bCNV, an internally developed tool, based on the depth of coverage information. The analysis of CNVs (minimum three consecutive exons) was included in all captured regions.</p>
        </sec>
        <sec id="Sec8">
          <title>Family 4</title>
          <p id="Par12">Exome sequencing, bioinformatics analysis, and variant filtering for the proband were performed as previously described (Zeng et al. <xref ref-type="bibr" rid="CR64">2022b</xref>). Copy number analysis was performed using DECoN (Fowler et al. <xref ref-type="bibr" rid="CR12">2016</xref>) with default settings and the BAM files from the same enrichment panel and sequencing run as controls. <italic>STRC</italic> copy number testing was performed using a PCR with exon 22 specific primers as previously described&#xA0;(Vona et al. <xref ref-type="bibr" rid="CR54">2015</xref>), and&#xA0;with MLPA analysis.</p>
        </sec>
      </sec>
      <sec id="Sec9">
        <title>Variant assessment and validation</title>
        <p id="Par13">All exome datasets were assessed without a retrospective search to find <italic>PKHD1L1</italic> biallelic variants. Exome data for the sequenced individuals in Families 1, 2, and 3 were filtered to remove all variants with an allele frequency of 0.01 or more in public databases. Coding and splice site variants were retained. Deleteriousness of the missense variants was assigned according to prediction from multiple software and supported by evolutionary conservation of the affected amino acid (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Due to pedigree structures, homozygous variants were considered first while heterozygous variants were observed later. In addition, variant analysis of the proband in Family 2 employed an in-house database (including more than 2,500 exome datasets). Variants with low allele frequency and deleterious prediction were classified using the hearing loss-adapted ACMG criteria (Oza et al. <xref ref-type="bibr" rid="CR37">2018</xref>) and prioritized for further allele segregation studies in the family.<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p><italic>PKHD1L1</italic> variants identified</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Family</th><th align="left">Chr8 genomic location (g.)</th><th align="left">cDNA (c.)</th><th align="left">Protein (p.)</th><th align="left">Zyg</th><th align="left">AF gnomAD (v.3.1.2)</th><th align="left">MAF gnomAD (v3.1.2)</th><th align="left">MAF Pop gnomAD (v3.1.2))</th><th align="left">AF gnomAD (v.2.1.1)</th><th align="left">MAF gnomAD (v.2.1.1)</th><th align="left">MAF Pop gnomAD (v2.1.1)</th><th align="left">TOPMed v8</th><th align="left">All-of-Us</th><th align="left">SIFT</th><th align="left">PP-2</th><th align="left">FATHMM</th><th align="left">MT</th><th align="left">REVEL</th><th align="left">CADD</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">109382539G&gt;A</td><td align="left">385G&gt;A</td><td align="left">Gly129Ser</td><td align="left">Het</td><td align="left">6.6e&#x2212;6</td><td align="left">1.5 e&#x2212;5</td><td align="left">European (non-Finnish)</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">3.7 e&#x2212;6</td><td align="left">6.0 e&#x2212;6</td><td align="left">0<sup>1</sup></td><td char="." align="char">0.995<sup>1</sup></td><td align="left">&#x2212;&#x2009;2.15<sup>1</sup></td><td align="left">0.99<sup>1</sup></td><td align="left">0.55<sup>2</sup></td><td align="left">26.2<sup>1</sup></td></tr><tr><td align="left">1</td><td align="left">109439077G&gt;T</td><td align="left">3941G&gt;T</td><td align="left">Gly1314Val</td><td align="left">Het</td><td align="left">3.7 e&#x2212;4</td><td align="left">7.2 e&#x2212;4</td><td align="left">Ashkenazi Jewish</td><td align="left">2.8 e&#x2212;4</td><td align="left">5.7 e&#x2212;4</td><td align="left">European (non-Finnish)</td><td align="left">3.7 e&#x2212;4</td><td align="left">3.5 e&#x2212;4</td><td align="left">0.004<sup>1</sup></td><td char="." align="char">0.98<sup>1</sup></td><td align="left">&#x2212;&#x2009;2.56<sup>1</sup></td><td align="left">1<sup>1</sup></td><td align="left">0.86<sup>1</sup></td><td align="left">26.6<sup>1</sup></td></tr><tr><td align="left">2</td><td align="left">109491899C&gt;T</td><td align="left">10141C&gt;T</td><td align="left">Arg3381Ter</td><td align="left">Hom</td><td align="left">2.0 e&#x2212;5</td><td align="left">1.9 e&#x2212;4</td><td align="left">East Asian</td><td align="left">4.3 e&#x2212;5</td><td align="left">2.1 e&#x2212;4</td><td align="left">East Asian</td><td align="left">5.3 e&#x2212;5</td><td align="left">4.1 e&#x2212;5</td><td align="left">&#x2013;</td><td char="." align="char">&#x2013;</td><td align="left">&#x2013;</td><td align="left">1<sup>1</sup></td><td align="left">&#x2013;</td><td align="left">39.0<sup>1</sup></td></tr><tr><td align="left">3</td><td align="left">109464269C&gt;A</td><td align="left">7437C&gt;A</td><td align="left">His2479Gln</td><td align="left">Hom</td><td align="left">9.9 e&#x2212;5</td><td align="left">3.1 e&#x2212;3</td><td align="left">South Asian</td><td align="left">2.2 e&#x2212;4</td><td align="left">1.8 e&#x2212;3</td><td align="left">South Asian</td><td align="left">2.6 e&#x2212;5</td><td align="left">1.8 e&#x2212;5</td><td align="left">0<sup>1</sup></td><td char="." align="char">0.88<sup>1</sup></td><td align="left">&#x2212;&#x2009;3.30<sup>1</sup></td><td align="left">0.04<sup>3</sup></td><td align="left">0.72<sup>1</sup></td><td align="left">22.9<sup>1</sup></td></tr><tr><td align="left">4</td><td align="left">109406478G&gt;A*</td><td align="left">c.1813G&gt;A</td><td align="left">Gly605Arg</td><td align="left">Het</td><td align="left">1.3 e&#x2212;5</td><td align="left">1.9 e&#x2212;4</td><td align="left">East Asian</td><td align="left">5.9 e&#x2212;5</td><td align="left">7.8 e&#x2212;4</td><td align="left">East Asian</td><td align="left">1.9 e&#x2212;5</td><td align="left">&#x2013;</td><td align="left">0.009<sup>1</sup></td><td char="." align="char">&#x2013;</td><td align="left">&#x2212;&#x2009;2.43<sup>1</sup></td><td align="left">0.99<sup>1</sup></td><td align="left">0.75<sup>1</sup></td><td align="left">33.0<sup>1</sup></td></tr><tr><td align="left">4</td><td align="left">109466608del17</td><td align="left">c.8452_8468del</td><td align="left">Leu2818TyrfsTer5</td><td align="left">Het</td><td align="left">2.6 e&#x2212;5</td><td align="left">7.7 e&#x2212;4</td><td align="left">East Asian</td><td align="left">7.3 e&#x2212;5</td><td align="left">1.0 e&#x2212;3</td><td align="left">East Asian</td><td align="left">6.8 e&#x2212;5</td><td align="left">2.6 e&#x2212;5</td><td align="left">&#x2013;</td><td char="." align="char">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">34.0<sup>1</sup></td></tr></tbody></table><table-wrap-foot><p>All variants are annotated according to NC_000008.11 (genomic) and NM_177531.6 (coding DNA). Residue position according to NP_803875.2 including the signal peptide (Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>)</p><p><italic>AF</italic> allele frequency, <italic>chr</italic> chromosome, <italic>MAF</italic> maximum allele frequency, <italic>MT</italic> MutationTaster, <italic>Pop</italic> population, <italic>PP2</italic> PolyPhen-2, <italic>Zyg</italic> zygosity</p><p>Pathogenicity is represented as <sup>1</sup>deleterious, <sup>2</sup>neutral, or <sup>3</sup>benign prediction, whereas &#x201C;&#x2013;&#x201D; represents variant not scored.*109406478G&gt;A is predicted by SpliceAI to affect splicing: 0.230 (donor_gain)</p></table-wrap-foot></table-wrap></p>
        <p id="Par14">Variants in the exome data of the&#xA0;proband in Family 4 were identified with SnpEff annotation. First, the following variant types were removed from the analysis: intergenic_region, upstream_gene_variant, downstream_gene_variant, 5_prime_UTR_variant, 3_prime_UTR_variant, intron_variant, and non_coding_transcript_exon. At the same time, variants with ada_score&#x2009;&gt;&#x2009;0.5 or rf_score&#x2009;&gt;&#x2009;0.5 and variants annotated as likely pathogenic, pathogenic, or VUS in ClinVar were retained. We then filtered out variants with minor allele frequency&#x2009;&gt;&#x2009;0.001 in any population in which at least 2,000 alleles were observed in the gnomAD database (v2.1.1), except those on the ACMG benign stand-alone exception list. We prioritized variants that occurred in the curated hearing loss associated gene list from the ClinGen Hearing Loss Gene Curation Expert Panel (DiStefano et al. <xref ref-type="bibr" rid="CR9">2019</xref>).</p>
        <p id="Par15">Variants were prioritized based on population&#xA0;frequencies and in silico pathogenicity software predictions. Variant minor allele frequencies were derived from gnomAD (v2.1.1 and v3.1.2, Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) (Chen et al. <xref ref-type="bibr" rid="CR4">2022</xref>; Karczewski et al. <xref ref-type="bibr" rid="CR21">2020</xref>). Various pathogenicity prediction tools were used including SIFT (Ng and Henikoff <xref ref-type="bibr" rid="CR35">2001</xref>), PolyPhen-2 (Adzhubei et al. <xref ref-type="bibr" rid="CR1">2010</xref>), FATHMM (Shihab et al. <xref ref-type="bibr" rid="CR50">2014</xref>), MutationTaster (Schwarz et al. <xref ref-type="bibr" rid="CR48">2014</xref>), REVEL (Ioannidis et al. <xref ref-type="bibr" rid="CR16">2016</xref>) and CADD (Rentzsch et al. <xref ref-type="bibr" rid="CR43">2019</xref>). Variants were analyzed for splice prediction using SpliceAI (Jaganathan et al. <xref ref-type="bibr" rid="CR17">2019</xref>), and visualization of amino acid substitution tolerance was supported by the MetaDome web server (Wiel et al. <xref ref-type="bibr" rid="CR57">2019</xref>).</p>
        <p id="Par16">Variants were annotated using the <italic>PHKD1L1</italic> NM_177531.6 accession number (ENST00000378402.9). The GTEx Portal (Consortium <xref ref-type="bibr" rid="CR6">2013</xref>) was referenced for assessing the location of variants across the annotated <italic>Hs PHKD1L1</italic> gene sequence (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1</xref>). <italic>PKHD1L1</italic> variant segregation in Families 1, 2, and 4 was confirmed using Sanger sequencing, but not for the proband in Family 3.</p>
      </sec>
      <sec id="Sec10">
        <title>Sequence analyses and structural modeling of PKHD1L1 protein</title>
        <p id="Par17">We compared PKHD1L1 protein sequences among ten different PKHD1L1 orthologs (NM_177531.6 and NP_803875.2 for <italic>Hs</italic> PKHD1L1, see Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref> for more details about the selected species). The sequences were obtained from the National Center for Biotechnology Information (NCBI) protein database (see Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref> for NCBI accession numbers). First, each individual protein sequence was used to predict their signal peptides and domains using the Simple Modular Architecture Research Tool (SMART) (Letunic et al. <xref ref-type="bibr" rid="CR26">2021</xref>). Signal peptides were further predicted using the SignalP-5.0 (Almagro Armenteros et al. <xref ref-type="bibr" rid="CR2">2019</xref>) and the Prediction of Signal Peptides (PrediSi) online servers (Hiller et al. <xref ref-type="bibr" rid="CR14">2004</xref>). AlphaFold2 modeling was used to predict the potential signal peptide cleavage site and accurately inform the start and end of each predicted domain before carrying out the protein sequence alignment (Mirdita et al. <xref ref-type="bibr" rid="CR33">2022</xref>). Since the PKHD1L1 Ig-like-plexins transcription factors (IPT) domains do not have a clear conservation pattern at their IPT protein start and end sequence and connecting linker domains, AlphaFold2 modeling results were combined with protein sequence alignment to better predict the signal peptide, IPT domain start and end residue positions, and the location of missense mutations.</p>
        <p id="Par18">The ClustalW algorithm (Larkin et al. <xref ref-type="bibr" rid="CR25">2007</xref>) on Geneious (Kearse et al. <xref ref-type="bibr" rid="CR22">2012</xref>) was used for the sequence identity analysis using the default parameters. Alignment files from Geneious were imported and color-coded in JalView with 35% conservation threshold, as previously described (Kearse et al. <xref ref-type="bibr" rid="CR22">2012</xref>). AlphaFold2 structural modeling of PKHD1L1 fragments were carried out using the Colabfold v1.5.2-patch server using default parameters (Mirdita et al. <xref ref-type="bibr" rid="CR33">2022</xref>).</p>
      </sec>
      <sec id="Sec11">
        <title>Cloning, expression, and purification of engineered bacterially expressed PKHD1L1 protein fragments and mutant constructs</title>
        <p id="Par19">The cDNA of wild-type (WT) <italic>Mus musculus</italic> (<italic>Mm</italic>) <italic>PKHD1L1</italic> IPT1-3 and IPT5-6 were subcloned into the <italic>Nde</italic>I and <italic>Xho</italic>I sites of the pET21a&#x2009;+&#x2009;vector. Next, the cDNA fragments were amplified from longer synthetized sequences optimized for <italic>E. coli</italic> expression. Site-directed mutagenesis was applied to engineer the <italic>Mm</italic> PKHD1L1 IPT1-3 p.(Gly129Ser) and PKHD1L1 IPT5-6 p.(Gly1314Val) constructs using the QuickChange lightning kit (Agilent Technologies). All constructs were used for protein expression in Rosetta (DE3) competent cells (Novagen) and cultured in TB as previously&#xA0;described (De-la-Torre et al. <xref ref-type="bibr" rid="CR7">2018</xref>). Expressed recombinant proteins were purified under denaturing conditions (6&#xA0;M guanidine) using nickel beads. Next, their purity was analyzed by sodium dodecyl sulfate&#x2013;polyacrylamide gel electrophoresis (SDS-PAGE) and refolded at 4&#xA0;&#xB0;C using previously reported conditions (De-la-Torre et al. <xref ref-type="bibr" rid="CR7">2018</xref>), briefly outlined below. WT <italic>Mm</italic> PKHD1L1 IPT1-3 and IPT1-3 p.(Gly129Ser) were refolded by fast or drop-wise dilution as previously reported for other protein families (De-la-Torre et al. <xref ref-type="bibr" rid="CR7">2018</xref>): 20&#xA0;mL of pure denatured protein (0.5&#x2013;1&#xA0;mg/mL) was dropped into 480&#xA0;mL of refolding buffer containing 20&#xA0;mM Tris&#x2013;HCl [pH 8.0], 150&#xA0;mM KCl, 50&#xA0;mM NaCl, 2&#xA0;mM CaCl<sub>2</sub>, 400&#xA0;mM L-arginine, and 2&#xA0;mM <italic>D</italic>(&#x2009;+) glucose. WT <italic>Mm</italic> PKHD1L1 IPT5-6 and IPT5-6 p.(Gly1314Val) were refolded by dialysis of 40&#xA0;mL of eluted denatured protein at 0.5&#xA0;mg/mL into 1000&#xA0;mL of refolding buffer (20&#xA0;mM Tris&#x2013;HCl [pH 7.5], 150&#xA0;mM KCl, 50&#xA0;mM NaCl, 5&#xA0;mM CaCl<sub>2</sub>, 400&#xA0;mM <sc>l</sc>-arginine, 1&#xA0;mM of glutathione oxidized). Proteins were concentrated using 10,000&#xA0;Da Amicon Ultra-15 centrifugal filters and purified using size exclusion chromatography (SEC) with an Akta Purifier System with the S200 16/600&#xA0;pg and S200 13/300 increase GL columns (GE Healthcare) in a buffer containing 20&#xA0;mM Tris&#x2013;HCl pH 7.5, 150&#xA0;mM KCl, 50&#xA0;mM NaCl, and 5&#xA0;mM CaCl<sub>2</sub> to preserve the most abundant endolymphatic cations. Following SEC, protein purity was further verified by SDS-PAGE.</p>
      </sec>
      <sec id="Sec12">
        <title>Nanoscale differential scanning fluorimetry (NanoDSF)</title>
        <p id="Par20">WT <italic>Mm</italic> PKHD1L1 IPT1-3 and IPT5-6 protein fragments and their respective missense IPT1-3 p.(Gly129Ser) and IPT5-6 p.(Gly1314Val) proteins were used for functional evaluation in vitro. Thermodynamic evaluation and folding stabilities of these constructs in solution were carried out using nanoscale differential scanning fluorimetry (NanoDSF). Pure proteins were concentrated to 0.5&#x2013;1&#xA0;mg/mL for NanoDSF using a Prometheus NT.48 (Nanotemper) and scanned between 20 and 95&#xA0;&#xB0;C with a pre-stabilization phase of 1 min and a temperature slope of 2&#xA0;&#xB0;C/min (37 min in total). Data were processed using a PR. ThermControl v2.1.2 software and plotted using GraphPad Prism. At least two biological replicates were used for each experiment. Each protein preparation was independently expressed and refolded at least two times (two biological replicates), and evaluated independently on NanoDSF. Each NanoDSF scan used at least four separate capillary tubes run in parallel for each biological replicate. Each result per biological replicate represents average values of these measurements. Protein folding analysis results were plotted as a relationship of the normalized F350/F330 (%) ratio intensities (<italic>T</italic><sub>onset</sub>). The first derivative of F350/F330 (%) intensities was plotted to obtain the thermal unfolding transition midpoints (<italic>T</italic><sub>m</sub>).</p>
      </sec>
      <sec id="Sec13">
        <title>Minigene assay of the c.1813G&#x2009;&gt;&#x2009;A, p.(Gly605Arg) variant</title>
        <p id="Par21">A minigene assay was performed as previously described (Zeng et al. <xref ref-type="bibr" rid="CR63">2022a</xref>). Briefly, the WT and mutated sequences (exon 17 and flanking intronic sequences) were cloned (MINI-PKHD1L1-Kpn1-F: 5&#x2032;-GGTAGGTACCAGGCC-3&#x2032;, 5&#x2032;-TATGGAACACCAATTTA-3&#x2032; and MINI-PKHD1L1-BamH1-R: 5&#x2032;-TAGTGGATCCAAT-3&#x2032; and 5&#x2032;-AAGGCCTGTCCTCAAATGTCT-3&#x2032;) following amplification from the DNA of the proband in Family 4 between exons A and B in the pcMINI plasmid. Next, the WT and mutated plasmids were transfected into both HEK293 and HeLa cells. The splicing effects were analyzed via RT-PCR and sequencing with vector-specific primers (PcMINI-F: 5&#x2032;-CTAGAGAACCCACTGCTTAC-3&#x2032; and PcMINI-R: 5&#x2032;-TAGAAGGCACAGTCGAGG-3&#x2032;).</p>
      </sec>
    </sec>
    <sec id="Sec14">
      <title>Results</title>
      <sec id="Sec15">
        <title>Clinical genetics and variant identification</title>
        <sec id="Sec16">
          <title>Family 1 (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>)</title>
          <fig id="Fig1">
            <label>Fig.&#xA0;1</label>
            <caption>
              <p>Pedigrees and audiograms. Pedigree and audiometric information for four families with biallelic <italic>PKHD1L1</italic> variations. <bold>a</bold> Pedigrees for Families 1&#x2013;4. Each proband with SNHL is indicated with shading and arrow. <bold>b</bold> Pure-tone audiometry for probands 1&#x2013;4; x represents results for the left ear and o represents the right. Audiometric evaluation performed at the age of 13-, 9-, 12-, and 8-years-old for probands 1&#x2013;4, respectively</p>
            </caption>
            <graphic xlink:href="439_2024_2649_Fig1_HTML" id="MO1"/>
          </fig>
          <p id="Par22">The proband is a 13-year-old white female from the United States born to healthy non-consanguineous parents. She did not pass a newborn hearing screen bilaterally. Pure-tone audiometry has been performed approximately every 6&#xA0;months and consistently demonstrated a slowly progressive mild to moderate SNHL bilaterally. Between the ages of 4.3&#xA0;years and 13.3&#xA0;years, there was an increase in pure-tone average (PTA) of 5&#xA0;dB for the right ear and 8&#xA0;dB for the left ear. PTA<sub>0.5&#x2013;4K</sub> was 41.25 and 38.75 in the right and left ears, respectively, at age 4. Most recent audiometric testing showed PTA of 45.00 and 48.75 in the right and left ears, respectively. Speech audiometry at most recent evaluation (age 13.3&#xA0;years) demonstrates a 90% word recognition at a comfortable listening level. Speech recognition threshold (SRT) is 45&#xA0;dB bilaterally. There was a history of episodes of benign paroxysmal positional vertigo (BPPV) which resolved after Epley maneuver. Imaging studies of the inner ear were not performed. An electrocardiogram and ophthalmology exam were normal. Cytomegalovirus testing performed at 13-weeks-old was negative. There were no dysmorphic facial features, neurological or developmental abnormalities, or other pertinent history. Exome sequencing was performed with an average depth of coverage of variants of 92 reads with 95.4% of variants covered with more than 20 reads. Exome sequencing revealed candidate variants only in <italic>PKHD1L1</italic> following the variant filtering methodology described. The proband was compound heterozygous for missense variants, c.385G&gt;A, p.(Gly129Ser) and c.3941G&gt;T, p.(Gly1314Val) (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) that segregated within the trio in a Mendelian recessive manner (residue numbering corresponds to the NCBI <italic>Hs</italic> PKHD1L1 sequence NP_803875.2 including the signal peptide, Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>).</p>
          <p id="Par23">The c.385G&gt;A, p.(Gly129Ser) substitution resides in exon 4 of 78 in <italic>PKHD1L1</italic> and has a maximum allele frequency (MAF) of 0.001471% in gnomAD (v3.1.2). This variant is predicted to be deleterious to protein structure and function via in silico predictors (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). This nonpolar glycine to polar serine substitution occurs at the tip of the PKHD1L1 IPT1 domain (N-terminal end) (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>b&#x2013;d). This locus is predicted to be somewhat tolerant to missense substitution (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2</xref>). On the other hand, the c.3941G&gt;T, p.(Gly1314Val), located in exon 32 of 78 in <italic>PKHD1L1,</italic> has a MAF of 0.07204% (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>, gnomAD, v3.1.2). It is suggested to be deleterious to protein structure and function by in silico prediction tools (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>), as well as predicted to be intolerant to missense substitution (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2</xref>). The p.(Gly1314Val) substitution is located at the PKHD1L1 IPT6 domain region (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>b&#x2013;e).<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>PKHD1L1 protein domain prediction and evolutionary analysis&#xA0;for missense variants (Family 1 and Family 3). <bold>a</bold> Schematic of a hair-cell stereocilia bundle under force stimulation highlighting the stereocilia surface coat. <bold>b</bold> Protein domain composition prediction from SMART using the <italic>Hs</italic> PKHD1L1 protein sequence as in NCBI accession code NP_803875.2, including the signal peptide (20 amino acids are predicted for <italic>Hs</italic> PKHD1L1 according to SMART. See Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>). Positions of each missense variant reported in this study are presented with a green arrowhead. The red star represents a newly predicted TMEM2-like domain. Black and purple arrow-headed lines represent the sequence fragments used for AlphaFold2 modeling of IPT1-2, IPT5-6, and TMEM2-like domain, respectively. <bold>c</bold> Topological description of <italic>Hs</italic> PKHD1L1 protein sequence as a reference. <bold>d</bold>, <bold>e</bold> Multiple protein sequence alignments comparing IPT1 and IPT6 domains among ten different PKHD1L1 orthologs, respectively (see Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref> for details about the selected species and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3</xref> for full PKHD1L1 sequence alignment). IPT1 has a pairwise sequence identity conservation of 82.3%, while IPT6 has a pairwise sequence identity of 74.9% across ten different orthologs. An independent % sequence identity analysis of only <italic>Hs</italic> and <italic>Mm</italic> species for IPT1 and IPT6 shows 82.9% and 77.8%, respectively (sequence alignment not shown). Missense variants are highlighted by green triangles. Blue circles represent cysteine residues forming disulfide bonds. Each alignment was color-coded for sequence similarity (35% threshold) using Jalview. White-colored residues report the lowest similarity and dark blue report the highest (see Methods). PKHD1L1 orthologs were chosen based on sequence availability and taxonomical diversity (Choudhary et al. <xref ref-type="bibr" rid="CR5">2020</xref>; De-la-Torre et al. <xref ref-type="bibr" rid="CR7">2018</xref>; Jaiganesh et al. <xref ref-type="bibr" rid="CR18">2018</xref>)</p></caption><graphic xlink:href="439_2024_2649_Fig2_HTML" id="MO2"/></fig></p>
        </sec>
      </sec>
      <sec id="Sec17">
        <title>Family 2 (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>)</title>
        <p id="Par24">The proband is a 9-year-old Iranian male of Lur ethnicity born to healthy consanguineous (first cousin) parents with subjectively normal hearing. Congenital SNHL was suspected and was clinically diagnosed at 2.5&#xA0;months. It has progressed to a bilateral moderate to severe degree. Pure-tone audiometry shows moderate to severe SNHL at all frequencies. Speech audiometry understanding is 100% at a comfortable listening level, and the otoacoustic emissions were present bilaterally. His SRT is 60&#xA0;dB and his speech discrimination score (SDS) is 100% at the intensity level of 80&#xA0;dB. The proband currently uses hearing aids bilaterally. There have been no vestibular abnormalities or delays in motor milestones. Exome sequencing was performed with an average depth of 66&#xD7;, with 75% of variants covered with more than 20 reads. Exome sequencing revealed that the proband was homozygous for the c.10141C&gt;T, p.(Arg3381Ter) nonsense variant (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) that resided in a&#x2009;~&#x2009;28&#xA0;Mb run of homozygosity. All other variants were excluded based on segregation (Supplementary Table <xref rid="MOESM1" ref-type="media">S2</xref>). Sanger sequencing at this locus confirmed the homozygous variant and revealed that the parents were both heterozygous carriers of the c.10141C&gt;T, p.(Arg3381Ter) substitution.</p>
        <p id="Par25">The c.10141C&gt;T, p.(Arg3381Ter) variant is located in exon 62 of 78 and identified with a MAF of 0.02067% in population databases (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>, gnomAD, v2.1.1). This variant occurs in a region with parallel beta-helix (Pbh1) repeats (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>b and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3</xref> for residue conservation), introducing a premature stop codon that is predicted to result in the loss of approximately 20% of the transcript (~&#x2009;882 amino acids), including the transmembrane domain, and could potentially cause nonsense mediated decay. However, if expressed in a truncated form, lack of the transmembrane domain is likely to impair proper localization of PKHD1L1 in the cell membrane or might induce unconventional secretion of PKHD1L1 protein fragments.</p>
      </sec>
      <sec id="Sec18">
        <title>Family 3 (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>)</title>
        <p id="Par26">The proband is a 12-year-old Pakistani male with congenital SNHL born to healthy consanguineous parents, and his audiometric testing demonstrated a bilateral severe SNHL (PTA<sub>0.5&#x2013;4K</sub> 85&#xA0;dB HL). No further follow-up was possible for the affected individual. Exome data had an average overall depth of 211&#xD7; and 99.1% of variants were covered by more than 20 reads. Exome analysis revealed two homozygous missense variants of interest: one in <italic>PKHD1L1</italic> c.7437C&gt;A, p.(His2479Gln) and one in <italic>MYO7A</italic> (NM_000260.4:c.1123C&gt;G, p.(Leu375Val)). Both <italic>MYO7A</italic> and <italic>PKHD1L1</italic> variants were of high quality and each was covered by more than 150 reads. The homozygous variant in <italic>MYO7A</italic>, with a coverage of 198 high quality reads, was deprioritized given uncertain and neutral in silico predictions with respect to impact on protein structure and function (Supplementary Table <xref rid="MOESM1" ref-type="media">S2</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S6</xref>). Moreover, the affected amino acid was not conserved in evolution, being isoleucine instead of leucine in some mammals, birds, and amphibians.</p>
        <p id="Par27">The c.7437C&gt;A, p.(His2479Gln) substitution in <italic>PKHD1L1</italic> is located in exon 49 of 78 and is identified at a MAF of 0.3107% in population databases (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>, gnomAD, v3.1.2). This positively charged histidine to neutral glutamine substitution is located in a topological region with an unpredicted domain structure per SMART prediction tool (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>b).</p>
      </sec>
      <sec id="Sec19">
        <title>Family 4 (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>)</title>
        <p id="Par28">The proband is an 8-year-old boy with SNHL born to healthy non-consanguineous parents from Henan Province, China. He presented to the First Affiliated Hospital of Zhengzhou University in 2023 with concern for hearing loss, and pure-tone audiometry demonstrated a bilateral moderate SNHL. DPOAEs were absent in both ears, and the tympanograms were normal, suggesting dysfunction of the outer hair cells. The hearing loss in this proband is thought to be congenital per parental report, but newborn hearing screening was not performed at the time of birth. The father had a pure-tone audiometric evaluation in 2019, at the age of 33&#xA0;years, which showed thresholds within the normal range.</p>
        <p id="Par29">The proband underwent exome sequencing at Precision Medicine Center of Zhengzhou University. Exome sequencing was performed with an average depth of 123.7&#xD7; for all variants, with 99.2% covered by more than 20 reads. The initial exome analysis was negative; sequencing data were reanalyzed after this manuscript was deposited as a preprint in medRxiv (Redfield et al. <xref ref-type="bibr" rid="CR41">2023</xref>). Reanalysis revealed compound heterozygous variants in <italic>PKHD1L1</italic>, with the missense variant c.1813G&gt;A, p,(Gly605Arg) inherited from the father, and a frameshift variant c.8452_8468del, p.(Leu2818TyrfsTer5) from the mother. The p.(Gly605Arg) missense variant was predicted to affect splicing by multiple tools, including dbNSFP (ada_score of 0.9998, and rf_score of 0.893), and SpliceAI (delta score of Donor Gain: 0.23). Interestingly, the same heterozygous missense variant c.1813G&gt;A, p,(Gly605Arg) was found in another genetically undiagnosed proband with congenital bilateral severe SNHL from the Henan cohorts. In addition, the frameshift variant c.8452_8468del, p,(Leu2818TyrfsTer5) was also found in a genetically diagnosed proband (heterozygous c.8452_8468del; <italic>MYO7A</italic> c.689C&gt;T, p.(Ala230Val), a known <italic>MYO7A</italic> pathogenic variant, (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/variation/178993/">https://www.ncbi.nlm.nih.gov/clinvar/variation/178993/</ext-link>) (Di Leva et al. <xref ref-type="bibr" rid="CR8">2006</xref>; Kaneko et al. <xref ref-type="bibr" rid="CR20">2017</xref>; Lezirovitz and Mingroni-Netto <xref ref-type="bibr" rid="CR28">2022</xref>) with congenital bilateral SNHL from the Henan cohorts.</p>
      </sec>
      <sec id="Sec20">
        <title>Investigating the conservation of the mutated residue positions throughout evolution</title>
        <p id="Par30">All missense variants do not appear to cluster in any particular region of the <italic>Hs</italic> PKHD1L1 that was used for alignment and further analysis (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1</xref>). In comparing the longest PKHD1L1 sequences among ten different orthologs, we uncovered an overall amino acid sequence identity of 79.2% (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3</xref>). Notably, <italic>Mm</italic> and <italic>Hs</italic> PKHD1L1 share 81.8% of amino acid sequence identity (when comparing for identical sites excluding the signal peptides), while <italic>Hs</italic> and <italic>Mm</italic> orthologs of IPT1 and IPT6 show 82.9% and 77.8%, respectively, suggesting high protein sequence conservation between the two species. Although some previous studies report protein sequence alignments and predictions of PKHD1L1 IPT domains (Hogan et al. <xref ref-type="bibr" rid="CR15">2003</xref>), an in-depth analysis was necessary to more accurately predict the signal peptide cleavage sites, as well as the starting and ending residues for each IPT domain. The locations of the native Gly126, Gly1314, and His2479 residues, where the reported missense variants were detected, are highly conserved across a diverse set of the ten different PKHD1L1 orthologs analyzed (Figs. <xref rid="Fig2" ref-type="fig">2</xref>d, e, <xref rid="Fig4" ref-type="fig">4</xref>a, and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3</xref> and Fig. <xref rid="MOESM1" ref-type="media">S4</xref>).</p>
      </sec>
      <sec id="Sec21">
        <title>AlphaFold2 modeling of PKHD1L1 substitutions</title>
        <p id="Par31">PKHD1L1 has 14 predicted IPT extracellular-domain repeats of similar fold but with non-identical protein sequences labeled as IPT1 to IPT14 from its N-terminal to C-terminal end, and other key domain features (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>b). The AlphaFold2 model of WT <italic>Hs</italic> IPT1-2 and its mutant p.(Gly129Ser) shows no apparent differences between their predicted structures (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a, b), likely because the small side chain carrying this residue is located on a loop region exposed to the solvent. More specifically, the p.(Gly129Ser) variant is located within the connecting loop between the &#x3B2;-strand 6&#x2013;7 of IPT1, close to a potential disulfide bond formed by p.Cys100 and p.Cys86, also found in plexin-like domains (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>b). Changes of the polarity or the electrostatic potential of this loop by p.(Gly129Ser) might cause structural changes or altered loop dynamics in IPT1 (Krieger et al. <xref ref-type="bibr" rid="CR23">2005</xref>). We also generated AlphaFold2 models for <italic>Hs</italic> IPT5-6 consistent with the expected IPT plexin-like folding for this structure (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>c&#x2013;e). According to this structural model, the <italic>Hs</italic> p.(Gly1314Val) mutation is also located at the connecting loop between the &#x3B2;-strand 6&#x2013;7 of IPT6 (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>c&#x2013;e). Furthermore, the p.(Gly1314Val) variant is located within the connecting area between IPT5 and IPT6, and the AlphaFold2 model suggests a structural change for this specific fragment (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>d, e).<fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>AlphaFold2 modeling of PKHD1L1 protein fragments carrying p.(Gly120Ser) and p.(Gly1314Val) mutations. <bold>a</bold> Superposed AlphaFold2 models of both native <italic>Hs</italic> IPT1-2 (orange) and <italic>Hs</italic> IPT1-2 p.(Gly120Ser) variant (mauve) are shown. <bold>b</bold> Higher magnification image of the mutated site. p.S129 in lime and p.G129 in cyan. No apparent structural changes are predicted by AlphaFold2. <bold>c</bold> Structural model of <italic>Hs</italic> IPT5-6 showing the native p.Gly1314 position. <bold>d</bold> Superposed <italic>Hs</italic> IPT5-6 (orange) and <italic>Hs</italic> IPT5-6 p.(Gly1314Val) (mauve) structures showing a structural change predicted by AlphaFold2 as a result of p.(Gly1314Val) substitution. &#x3B2;-strands and loops do not overlap, with a dashed black arrow reporting the loop shift. <bold>e</bold> Higher magnification image of the mutated site showing the conformation change of &#x3B2;-strands and loops. p.V1314 (lime) causes steric hindrance in the area inducing an expanded conformation to the variant structure in mauve. See dashed arrows</p></caption><graphic xlink:href="439_2024_2649_Fig3_HTML" id="MO4"/></fig></p>
        <p id="Par32">In a previous study, authors used protein sequence analysis of PKHD1, PKHD1L1, and TMEM2 reporting that PKHD1 and PKHD1L1 share two regions of significant sequence homology with TMEM2 (Hogan et al. <xref ref-type="bibr" rid="CR15">2003</xref>). AlphaFold2 modeling of the p.(His2479Gln) variant and surrounding PKHD1L1 region revealed a high structural homology with a <italic>Hs</italic> TMEM2 protein (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). We identified that this region features a conserved p.His2479 residue (throughout ten different PKHD1L1 orthologs, Supplementary Fig. <xref rid="MOESM1" ref-type="media">S4</xref>) (p.His552 in <italic>Hs</italic> TMEM2, Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>a; Protein Data Bank (PDB): 8C6I (Niu et al. <xref ref-type="bibr" rid="CR36">2023</xref>)) reported to form a nickel-finger binding site, which might mediate catalytic functions in TMEM2. Disruption of this site in PKHD1L1 and TMEM2 might impair cation binding (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>a&#x2013;f and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3</xref> and <xref rid="MOESM1" ref-type="media">S4</xref>) and suggests a potential deleterious effect for this variant on protein structure and function. This locus is predicted neutral in terms of tolerance to missense substitution (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2</xref>).<fig id="Fig4"><label>Fig.&#xA0;4</label><caption><p>PKHD1L1 structural modeling of the protein fragment containing the p.(His2479Gln) variant. Based on AlphaFold2 predictions, this fragment of PKHD1L1 shares a common fold with the TMEM2 protein within the region carrying the p.(His2479Gln) variant. <bold>a</bold> Protein sequence alignment of a protein segment of <italic>Hs</italic> TMEM2 against ten different PKHD1L1 orthologs (see Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref> for details of the selected species, Supplementary Fig. <xref rid="MOESM1" ref-type="media">S4</xref> for sequence alignment of this specific fragment, and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3</xref> for full PKHD1L1 sequence alignment). Residue numbering for TMEM2 as in PDB: 8C6I (Niu et al. <xref ref-type="bibr" rid="CR36">2023</xref>), while residue numbering for <italic>Hs</italic> PKHD1L1 as in NCBI accession code NP_803875.2 with the signal peptide included (Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>, 26 residues are suggested according to protein sequence alignment, see Methods). Green triangles point to the location of the <italic>Hs</italic> p.(His2479Gln) variant, orange circles (<italic>left</italic>) indicate 100% amino acid sequence identity for this PKHD1L1 fragment between the <italic>Hs</italic>, <italic>Pt</italic>, and <italic>Mm2</italic> species (See supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref> for details about the selected orthologs). Green circles represent depicted residues in panels b&#x2013;e. The alignment was color-coded for sequence similarity (35% threshold) using Jalview. White-colored residues show the lowest similarity and dark blue report the highest (see Methods). PKHD1L1 orthologs were chosen based on sequence availability and taxonomical diversity. <bold>b</bold> The simulated protein structure covering the protein fragment highlighted by purple arrow-headed line in Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>b. Front view of the structure showing IPT14 linked to the PKHD1L1 TMEM2-like domain. The red star points to the linker connection. Residues at the mutation site are depicted as cyan sticks. <bold>c</bold> Side view from <italic>panel a</italic> showing a clear view of the stacked &#x3B2;-strand motifs. <bold>d</bold> Superposed structural protein alignment between WT <italic>Hs</italic> PKHD1L1 TMEM2-like domain model (orange) with the X-ray crystal structure of <italic>Hs</italic> TMEM2 protein (PDB: 8C6I, magenta). Residues at the native TMEM2-histidine-finger site are depicted as green sticks. <bold>e</bold> Higher magnification image of the potential conserved histidine-finger site between PKHD1L1 (orange) and TMEM2 (magenta) protein fragments and the Ni<sup>2+</sup> ion shown as lime sphere. <bold>f</bold> Displayed residues between both proteins surrounding the Ni<sup>2+</sup>-ion site highlighted in <italic>panel a</italic> in green circles</p></caption><graphic xlink:href="439_2024_2649_Fig4_HTML" id="MO3"/></fig></p>
      </sec>
      <sec id="Sec22">
        <title>Functional testing of the p.(Gly129Ser) and p.(Gly1314Val) substitutions</title>
        <p id="Par33">Next, we expressed and purified the recombinant WT <italic>Mm</italic> PKHD1L1 IPT1-3 and IPT5-6 protein fragments as well as the respective IPT1-3 p.(Gly129Ser) and IPT5-6 p.(Gly1314Val) mutant protein fragments using SEC (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S5</xref>). These protein constructs represent key regions of the complete extracellular domain of PKHD1L1 where these mutations might locally affect the structural assembly of the protein. The thermodynamic and folding stabilities were measured using NanoDSF to assess the protein stabilities in solution for WT PKHD1L1 protein fragments and compared to fragments carrying missense mutations (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S5</xref>). For WT IPT1-3, the T<sub>onset</sub> (melting temperature at which unfolding begins) was measured at a maximum of 58&#xA0;&#xB0;C, while the T<sub>onset</sub> for IPT1-3 p.(Gly129Ser) variant was 52&#xA0;&#xB0;C (a 6&#xA0;&#xB0;C decrease, Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S5</xref>). In addition, there was a decrease on the T<sub>m</sub> (melting temperature or point at which 50% of the protein is unfolded) of&#x2009;~&#x2009;4&#xA0;&#xB0;C comparing different thermal transition points between WT and the IPT1-3 p.(Gly129Ser) variant (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>a). These measurements strongly suggest that the p.(Gly129Ser) variant affects PKHD1L1 protein stability within this region.<fig id="Fig5"><label>Fig.&#xA0;5</label><caption><p>Thermodynamic and folding stability evaluation of two missense variants using NanoDSF. <bold>a</bold> NanoDSF melting temperatures for WT <italic>Mm</italic> IPT1-3 (orange) and <italic>Mm</italic> IPT1-3 p.(Gly129Ser) variant (pink). Measurements show at least three T<sub>m</sub> peaks (orange dotted line) for the WT IPT1-3, likely because the protein fragment includes multiple IPT domains that unfold sequentially. Measured T<sub>m</sub> values are shifted to the left (pink dotted line) showing a decrease of the thermal-folding stability. Temperatures are labeled for each T<sub>m</sub> transition point. <bold>b</bold> Results for WT <italic>Mm</italic> IPT5-6 and <italic>Mm</italic> IPT5-6 p.(Gly1314Val) showing a reduced thermal stability (TWO replicates, see Methods section). Traces correspond to the normalized first derivate of the fluorescence ratio showing the inflection point of the fluorescence ratio, which corresponds to the melting temperature of the sample. T<sub>onset</sub> values and protein purification experiments are shown in Supplementary Fig. <xref rid="MOESM1" ref-type="media">S5</xref></p></caption><graphic xlink:href="439_2024_2649_Fig5_HTML" id="MO5"/></fig></p>
        <p id="Par34">Similarly, NanoDSF measurements for WT <italic>Mm</italic> PKHD1L1 IPT5-6 and <italic>Mm</italic> IPT5-6 p.(Gly1314Val) showed a <italic>T</italic><sub>onset</sub> of 35.48&#xA0;&#xB0;C and 28.56&#xA0;&#xB0;C, respectively (~&#x2009;7&#xA0;&#xB0;C decrease, Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S5</xref>). In addition, WT <italic>Mm</italic> PKHD1L1 IPT5-6 showed a melting temperature <italic>T</italic><sub>m</sub> of 45.10&#xA0;&#xB0;C, while the mutant IPT5-6 p.(Gly1314Val) displayed a decrease on this <italic>T</italic><sub>m</sub> to 36.0&#xA0;&#xB0;C (decreasing the temperature&#x2009;~&#x2009;9.1&#xA0;&#xB0;C) (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>b). These results confirm that both IPT1-3 p.(Gly129Ser) and IPT5-6 p.(Gly1314Val) variants indeed significantly decrease the thermal and folding stabilities of these PKHD1L1 protein fragments.</p>
      </sec>
      <sec id="Sec23">
        <title>Splicing evaluation of p.(Gly605Arg)</title>
        <p id="Par35">Based on in silico evaluation (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>), the missense variant p.(Gly605Arg) was predicted to affect splicing given that it occurs at the 3&#x2019; exon boundary of exon 17 adjacent to the 5&#x2019; intronic splice donor site of intron 17 (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>). RNA studies of this variant indicated a functional effect on splicing, leading to an in-frame deletion of 48 amino acids (r.1670_1813del, p.Val557_Arg604del; Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig6"><label>Fig.&#xA0;6</label><caption><p>Minigene splicing assay for evaluation of the functional effect of p.(Gly605Arg) on splicing. <bold>a</bold> Schematic demonstrating designed minigene assay including CMV promotor, variant location, and primers. <bold>b</bold> Schematic showing calculated size of the&#xA0;fragment with exon 17 included (533&#xA0;bp) or excluded (389&#xA0;bp). <bold>c</bold>, <bold>d</bold> RT-PCR result from HEK293 and HeLa cells transfected with both WT and mutant plasmids showing different fragment lengths as well as sequence on chromatogram demonstrating lack of incorporation of exon 17 in cells transfected with the mutant plasmid, leading to in-frame deletion of 48 amino acids (p.Val557_Arg604del) using the NCBI NP_803875.2 as a reference sequence</p></caption><graphic xlink:href="439_2024_2649_Fig6_HTML" id="MO6"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec24">
      <title>Discussion</title>
      <p id="Par36">A majority of congenital SNHL is attributable to a genetic etiology, and clinical genetic testing for known SNHL genes is an established standard of care in the diagnostic evaluation of bilateral SNHL in pediatric patients (Shearer and Smith <xref ref-type="bibr" rid="CR49">2015</xref>; Smith et al. <xref ref-type="bibr" rid="CR53">2005</xref>). To date, there are over 120 known genetic causes of nonsyndromic hearing loss, and gene panel tests are recommended to facilitate accurate and timely genetic diagnosis of SNHL (<ext-link ext-link-type="uri" xlink:href="https://hereditaryhearingloss.org">https://hereditaryhearingloss.org</ext-link>). However, despite advances in genetic testing for SNHL, the diagnostic yield for SNHL ranges from 22.5 to 55.7% with an average of&#x2009;~&#x2009;40% (Downie et al. <xref ref-type="bibr" rid="CR10">2020</xref>; Perry et al. <xref ref-type="bibr" rid="CR38">2023</xref>; Rouse et al. <xref ref-type="bibr" rid="CR45">2022</xref>; Sloan-Heggen et al. <xref ref-type="bibr" rid="CR52">2016</xref>). The identification of novel hearing loss genes is critical to improving diagnostic rates, thus impacting care and management for individuals with SNHL.</p>
      <p id="Par37">In mice, PKHD1L1 is predominantly expressed in the OHC stereocilia by P0 to P12 with a basal-to-apical (decreasing) expression gradient and is a major component of the stereocilia surface coat (Wu et al. <xref ref-type="bibr" rid="CR58">2019</xref>). <italic>Pkhd1l1</italic>-deficient mice lack the surface coat at the stereocilia tips and exhibit progressive SNHL by ABR and DPOAE measurements starting as early as 3&#xA0;weeks. Although its function remains largely undetermined, the two functional hypotheses of PKHD1L1 expression at the stereocilia include that it may be required for the correct localization of other stereociliary proteins, or it plays a role during the development of attachment crowns at the stereocilia to secure the tectorial membrane to the bundle. An immature attachment could manifest as a persisting relaxed tectorial membrane coupling (Wu et al. <xref ref-type="bibr" rid="CR58">2019</xref>). Furthermore, it is unknown whether PKHD1L1 is the only component of the stereocilia coat. Recently, <italic>pkhd1l1</italic> was shown to play a critical role in regulating hearing in zebrafish (Makrogkikas et al. <xref ref-type="bibr" rid="CR30">2023</xref>). <italic>pkhdl1l</italic> has a ubiquitous expression pattern and is sustained for most of embryonic development (Makrogkikas et al. <xref ref-type="bibr" rid="CR30">2023</xref>). Through depletion of the two paralogous genes (<italic>pkhd1l1a</italic> and <italic>pkhd1l1b</italic>), double mutant zebrafish exhibited significant hearing loss from the larval stage (6&#xA0;days post fertilization) which differs compared to progressive hearing loss in the mouse (Wu et al. <xref ref-type="bibr" rid="CR58">2019</xref>).</p>
      <p id="Par38">Although presenting congenitally in the majority of patients, the degree of hearing impairment in the patients we present is fairly broad: the proband in Family 1, with p.[(Gly129Ser)];p.[(Gly1314Val)] compound heterozygous variants, was diagnosed with congenital hearing impairment that remains mild to moderate at the age of 13&#xA0;years; the proband in Family 2, with a homozygous p.(Arg3381Ter) variant, already showed moderate to severe SNHL at the age of 9&#xA0;years; and the proband in Family 3, at the age of 12&#xA0;years, showed severe hearing impairment attributed to the homozygous p.(His2479Gln) variant. However, in the&#xA0;case of the proband in Family 3 with the PKHD1L1&#xA0;p.(His2479Gln) variant, it is possible that, notwithstanding neutral predictions by different software packages (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>, and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2</xref>), the detected MYO7A p.(Leu375Val) missense variant is pathogenic (Supplementary Table <xref rid="MOESM1" ref-type="media">S2</xref>) and the <italic>PKHD1L1</italic> variant is an incidental finding, or both <italic>MYO7A</italic> and <italic>PKHD1L1</italic> variants may contribute to the more severe hearing loss of this individual. However, AlphaFold2 modeling showed that the MYO7A p.(Leu375Val) variant might not induce structural changes in MYO7A (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S6</xref>). The proband in Family 4 with p.[(Gly605Arg);p.(Leu2818TyrfsTer5)] compound heterozygous variants had a moderate hearing loss at the age of 8&#xA0;years.</p>
      <p id="Par39">While we have identified individuals in four families with variants in <italic>PKHD1L1</italic>, this study highlights the necessity for an extended case series with longitudinal audiological follow-up and functional studies to assess variant effects of patient-specific perturbations on development, maturation, and function of the auditory system, as well as explore the potential of accelerated effects of age, noise, or trauma on progression of hearing loss, which remain as current major limitations. Interestingly, the <italic>PKHD1L1</italic> gene has been suggested to be associated with adult&#x2010;onset hearing loss (Lewis et al. <xref ref-type="bibr" rid="CR27">2023</xref>). Since the studied variants are also located in different residue positions in the PKHD1L1 protein sequence, the broad range of hearing impairment from these patients might suggest that these variants differentially impact the protein expression, folding, and/or the stability and function of PKHD1L1. Therefore, we cannot exclude an environmental component that may account for variability.</p>
      <p id="Par40">We also investigated the conservation of the mutated residue positions throughout evolution. Multiple sequence alignments of the complete PKHD1L1 amino acid sequences from ten different orthologs were analyzed and found to be highly conserved. This suggests that these native residues might be critical to protein folding and assembly. Therefore, variants in these positions might disrupt protein function and potentially cause hearing impairment in vivo.</p>
      <p id="Par41">Because the p.(Arg3381Ter) introduces a stop codon that would be predicted to be targeted by nonsense mediated decay by the 50-nucleotide rule (Frischmeyer and Dietz <xref ref-type="bibr" rid="CR13">1999</xref>), it is anticipated that this would result in the lack of protein or low yield of truncated protein expression without the transmembrane domain, key for the proper insertion into the cell membrane. This is likely to impair the proper folding, trafficking, and insertion of PKHD1L1 in the stereocilia-plasma membrane, or even result in secretion of PKHD1L1 extracellular fragments that could progressively affect hearing function. Interestingly, secreted versions of extracellular PKHD1L1 have been found in supernatant solution from platelet cells (Maynard et al. <xref ref-type="bibr" rid="CR31">2007</xref>) and their soluble concentrations could be modulated by protease inhibitors (Fong et al. <xref ref-type="bibr" rid="CR11">2011</xref>), suggesting potential cleavage sites in <italic>Hs</italic> PKHD1L1. However, the role of these potentially cleaved extracellular PKHD1L1 protein fragments remains unknown.</p>
      <p id="Par42">To further predict how these PKHD1L1 mutant variants might affect the PKHD1L1 protein at the structural level, we modeled the structures of the individual domains carrying reported variants (Figs. <xref rid="Fig3" ref-type="fig">3</xref>a&#x2013;e, <xref rid="Fig4" ref-type="fig">4</xref>b&#x2013;e). The p.(Gly129Ser) substitution in IPT1 was not predicted to exert an apparent structural difference. We speculate that, instead, changes of the polarity or the electrostatic potential of the &#x3B2;-strand linker loop by p.(Gly129Ser) might alter loop dynamics in IPT1. Interestingly, both glycine substitutions p.(Gly129Ser) and p.(Gly1314Val) are located within the same connecting loop between &#x3B2;-strand 6&#x2013;7 in IPT1 and IPT6, respectively. While the AlphaFold2 model of the p.(Gly129Ser) mutant shows no apparent structural changes in the predicted structure (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a, b), the AlphaFold2 model of p.(Gly1314Val) shows a conformation change, likely due to steric hindrance on the structure (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>c&#x2013;e). Finally, we also mapped the location of the p.(His2479Gln) using structural modeling by AlphaFold2 (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>, Supplementary Fig. <xref rid="MOESM1" ref-type="media">S4</xref>). Our results indicate that the p.His2479 position (among ten different PKHD1L1 orthologs) is 100% conserved with a <italic>Hs</italic> TMEM2 protein (PDB: 8C6I), a regulator of the hyaluronan metabolism (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>a, e, f) (Sato et al. <xref ref-type="bibr" rid="CR47">2023</xref>). Interestingly, experiments suggest that TMEM2 activity is calcium dependent (Yamamoto et al. <xref ref-type="bibr" rid="CR59">2017</xref>) and TMEM2 has been previously studied for its structural similarities with the <italic>CEMIP</italic> deafness gene candidate (Yoshida et al. <xref ref-type="bibr" rid="CR61">2013</xref>).</p>
      <p id="Par43">Our NanoDSF thermal-folding analysis showed that both T<sub>onset</sub> and T<sub>m</sub> values decreased in the presence of the p.(Gly129Ser) and p.(Gly1314Val) variants. The T<sub>m</sub> measurements using NanoDSF showed p.(Gly129Ser), located in a loop, decreases the stability of IPT1 and further showed how this variant propagates its destabilizing effects to the neighboring IPT2 and IPT3 (Figs. <xref rid="Fig2" ref-type="fig">2</xref>b, <xref rid="Fig5" ref-type="fig">5</xref>, and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S5</xref>). Likely, the p.(Gly1314Val) variant also alters the stability of the loop and the chemical environment in the IPT5-IPT6 connection, since the measured folding stability showed a 9.1&#xA0;&#xB0;C decrease of unfolding temperature between WT IPT5-6 fragment and the p.(Gly1314Val) variant (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). This is the first study showing strong evidence to support how missense variants locally affect the structural folding and stability of PKHD1L1 fragments in vitro. Given the high conservation rate of 81.8% in amino acid sequence identity between the <italic>Hs</italic> and <italic>Mm</italic> PKHD1L1 (excluding the 20 amino acid long signal peptide according to SMART, Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3</xref>), and the 100% conservation of the mutated sites across the species analyzed, we believe our findings using <italic>Mm</italic> PKHD1L1 protein fragments can be directly applied to <italic>Hs</italic> PKHD1L1. Future functional studies involving highly conserved full-length PKHD1L1 orthologs and their protein purification would allow for better understanding of various effects such variants might have on the stability of the entire PKHD1L1 extracellular domain, its protein expression, and proper localization, which might be linked to the progression and hearing loss severity. Furthermore, studies focused on uncovering the influence of mutations on the structure of the complete PKHD1L1 extracellular domain will help to better understand the role of PKHD1L1 in hearing function and beyond, since the PKHD1L1 has been suggested as a tumor suppressor (Yang et al. <xref ref-type="bibr" rid="CR60">2023</xref>) and a human cancer biomarker (Kafita et al. <xref ref-type="bibr" rid="CR19">2023</xref>; Wang et al. <xref ref-type="bibr" rid="CR56">2023</xref>; Zheng et al. <xref ref-type="bibr" rid="CR65">2019</xref>).</p>
      <p id="Par44">As we have shown that single point mutations have a detrimental effect on protein folding and stability in protein fragments using NanoDSF, the deletion of longer protein motifs in PKHD1L1 extracellular domain might contribute to a more detrimental effect. In this case, the in vitro evidence presented in this study for the PKHD1L1 p.(Gly605Arg) missense variant found in the proband of Family 4 (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>, inherited from the father) strongly supports that this post-transcriptional splicing modification leads to an in-frame deletion of 48 amino acids (p.Val557_Arg604) (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>). This could explain the more significant hearing deficit caused by the p.(Gly605Arg) splicing mutation along with the frameshift variant c.8452_8468del, p.(Leu2818TyrfsTer5) (inherited from the mother) in the same individual, compared to the milder hearing loss phenotype presented in the proband in Family 1 (compound heterozygous p.[(Gly129Ser)];p.[(Gly1314Val)]).</p>
      <p id="Par45">Additional syndromic involvement was excluded in all four probands. However, in addition to hearing impairment, disruption of PKHD1L1 has also been associated with increased susceptibility to pentylenetetrazol-induced seizures in mice, indicating a possible role in maintenance of neuronal excitability in the central nervous system (Yu et al. <xref ref-type="bibr" rid="CR62">2023</xref>). It is currently unknown whether defects in <italic>PKHD1L1</italic> might cause sensory auditory seizures. However, PKHD1L1 is expressed in the hippocampus and cerebral cortex in adult WT mice. Knockdown of <italic>Pkhd1l1</italic> using <italic>PKHD1L1</italic>-shRNA or <italic>PKHD1L1</italic>-shRNA-AAV increased susceptibility of seizures as indicated by increased epileptiform bursting activity in cultured hippocampal neurons and pentylenetetrazol-induced seizures of mice following knockdown, suggesting a role for PKHD1L1 in the maintenance of normal excitation-inhibition balance (Yu et al. <xref ref-type="bibr" rid="CR62">2023</xref>). Knockdown of <italic>Pkhd1l1</italic> led to the downregulation of both expression and function of the KCC2 membrane protein, which may explain the increased susceptibility to seizures (Yu et al. <xref ref-type="bibr" rid="CR62">2023</xref>). There is no evidence that mutations in <italic>PKHD1L1</italic> lead to seizures in humans, though an open question remains as to whether similar pleiotropic effects paralleling, for example, the various phenotypes caused by pathogenic variants in <italic>TBC1D24</italic> may also occur as more <italic>PKHD1L1</italic> patients are discovered (Mucha et al. <xref ref-type="bibr" rid="CR34">1993</xref>; Rehman et al. <xref ref-type="bibr" rid="CR42">2017</xref>).</p>
    </sec>
    <sec id="Sec25">
      <title>Conclusion</title>
      <p id="Par46">Here we provide data to support that mutations in <italic>PKHD1L1</italic> cause human nonsyndromic autosomal recessive congenital, mild&#x2013;moderate to severe SNHL. We demonstrated that all reported missense variants point to highly conserved residues throughout evolution, suggesting that the native residues are key for protein folding and function, while variants in these sites locally affect the thermal-folding stability of PKHD1L1 fragments in solution. Inclusion of <italic>PKHD1L1</italic> as a hearing loss gene is supported by four families segregating plausible variants, in vitro functional data confirming their detrimental impact, as well as previously published mouse and zebrafish models demonstrating hearing loss. This study serves as a call to clinical laboratories to include careful screening of <italic>PKHD1L1</italic> biallelic variants in patients with a hearing loss ranging from mild&#x2013;moderate to severe. Further research will be needed to determine the effect of age or&#xA0;noise&#xA0;trauma on the potential progression of PKHD1L1-linked hearing loss.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <sec id="Sec26">
        <title>Supplementary Information</title>
        <p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="439_2024_2649_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 20695 KB)</p></caption></media></supplementary-material></p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher's Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
      <fn>
        <p>Shelby E. Redfield and Pedro De-la-Torre are shared first authors. Mina Zamani and Hanjun Wang are shared second authors. Artur A. Indzhykulian, A. Eliot Shearer and Barbara Vona are shared senior authors.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank the families for their participation. We thank Mahdiyeh Behnam for support with CNV analysis for the proband in Family 2&#xA0;and Dr. Jonathan Bird for advice on modeling of the <italic>MYO7A</italic> variant.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>SER and PD contributed equally as shared first authors, MZ and HW contributed equally as second authors, and AAI, AES, and BV contributed equally as shared last authors. AES, PD, and AAI conceived the study. PD, TM, and AAI designed methodology. PD and TM contributed to software. MZ, PD, and AAI performed formal analyses that were validated by HG, MK, PD, TM, and AAI. MZ, HW, HK, MK, SN, MAK, PD, TM, AAI, and BV conducted the investigation process. HG, GS, MAK, HX, WL, AES, SER, and PD secured patient and experimental resources. MZ, HW, HG, GS, BV, SER, WL, AES, PD, and AAI performed data curation. BV, AES, PD, and AAI wrote the original draft. MZ, HK, MK, SN, HG, BV, SER, AES, PD, and AAI contributed to reviewing and editing. BV, AES, SER, PD, and AAI prepared figures. SN, AES, PD, and AAI provided supervision. BV, AES, and AAI oversaw project administration. All authors reviewed and approved the manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>Open Access funding enabled and organized by Projekt DEAL. This work was supported by NIDCD K08 DC019716 to AES, the De Garay Family Fund to MAK with support from the Boston Children&#x2019;s Rare Disease Cohort Initiative, and the German Research Foundation (DFG) VO 2138/7-1 grant 469177153 to BV, and by NIH R01DC017166 (NIDCD) and R01DC020190 (NIDCD) to AAI. Funding for work in Pakistan was provided by the University of the Punjab (SN).</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.</p>
    </notes>
    <notes>
      <title>Declarations</title>
      <notes id="FPar2" notes-type="COI-statement">
        <title>Conflict of interest</title>
        <p id="Par47">Go Hun Seo is an employee of 3Billion, Inc. The other authors have no conflicts to declare.</p>
      </notes>
      <notes id="FPar3">
        <title>Consent to participate</title>
        <p id="Par48">Written informed consent was obtained from all participants.</p>
      </notes>
      <notes id="FPar4">
        <title>Consent to publish</title>
        <p id="Par49">Consent to publish was obtained from all participants.</p>
      </notes>
      <notes id="FPar5">
        <title>Ethics approval</title>
        <p id="Par50">This study was approved by the institutional review boards of Boston Children&#x2019;s Hospital (IRB P-00031494), University Medical Center G&#xF6;ttingen (No. 3/2/16), and the School of Biological Sciences, University of Punjab, Lahore, Pakistan (IRB No. 00005281).</p>
      </notes>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adzhubei</surname><given-names>IA</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Peshkin</surname><given-names>L</given-names></name><name><surname>Ramensky</surname><given-names>VE</given-names></name><name><surname>Gerasimova</surname><given-names>A</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Kondrashov</surname><given-names>AS</given-names></name><name><surname>Sunyaev</surname><given-names>SR</given-names></name></person-group><article-title>A method and server for predicting damaging missense mutations</article-title><source>Nat Methods</source><year>2010</year><volume>7</volume><fpage>248</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1038/nmeth0410-248</pub-id><pub-id pub-id-type="pmid">20354512</pub-id>
</element-citation>
      </ref>
      <ref id="CR2">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almagro Armenteros</surname><given-names>JJ</given-names></name><name><surname>Tsirigos</surname><given-names>KD</given-names></name><name><surname>Sonderby</surname><given-names>CK</given-names></name><name><surname>Petersen</surname><given-names>TN</given-names></name><name><surname>Winther</surname><given-names>O</given-names></name><name><surname>Brunak</surname><given-names>S</given-names></name><name><surname>von Heijne</surname><given-names>G</given-names></name><name><surname>Nielsen</surname><given-names>H</given-names></name></person-group><article-title>SignalP 5.0 improves signal peptide predictions using deep neural networks</article-title><source>Nat Biotechnol</source><year>2019</year><volume>37</volume><fpage>420</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0036-z</pub-id><pub-id pub-id-type="pmid">30778233</pub-id>
</element-citation>
      </ref>
      <ref id="CR3">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brownell</surname><given-names>WE</given-names></name></person-group><article-title>Outer hair cell electromotility and otoacoustic emissions</article-title><source>Ear Hear</source><year>1990</year><volume>11</volume><fpage>82</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1097/00003446-199004000-00003</pub-id><pub-id pub-id-type="pmid">2187727</pub-id>
</element-citation>
      </ref>
      <ref id="CR4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Francioli</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Goodrich</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Kanai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Alf&#xF6;ldi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Watts</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Vittal</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gauthier</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Poterba</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Tarasova</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Phu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Yohannes</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Koenig</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Farjoun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Banks</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Donnelly</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gabriel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ferriera</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tolonen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Novod</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bergelson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Roazen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ruano-Rubio</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Covarrubias</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Llanwarne</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Petrillo</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wade</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Jeandet</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Munshi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tibbetts</surname>
              <given-names>K</given-names>
            </name>
            <collab>Consortium gP</collab>
            <name>
              <surname>O&#x2019;Donnell-Luria</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Solomonson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Seed</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Talkowski</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Rehm</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Daly</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Tiao</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Neale</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>MacArthur</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Karczewski</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>A genome-wide mutational constraint map quantified from variation in 76,156 human genomes</article-title>
          <source>bioRxiv</source>
          <year>2022</year>
          <volume>261</volume>
          <fpage>14025</fpage>
          <pub-id pub-id-type="doi">10.1101/2022.03.20.485034</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhary</surname><given-names>D</given-names></name><name><surname>Narui</surname><given-names>Y</given-names></name><name><surname>Neel</surname><given-names>BL</given-names></name><name><surname>Wimalasena</surname><given-names>LN</given-names></name><name><surname>Klanseck</surname><given-names>CF</given-names></name><name><surname>De-la-Torre</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Araya-Secchi</surname><given-names>R</given-names></name><name><surname>Tamilselvan</surname><given-names>E</given-names></name><name><surname>Sotomayor</surname><given-names>M</given-names></name></person-group><article-title>Structural determinants of protocadherin-15 mechanics and function in hearing and balance perception</article-title><source>Proc Natl Acad Sci USA</source><year>2020</year><volume>117</volume><fpage>24837</fpage><lpage>24848</lpage><pub-id pub-id-type="doi">10.1073/pnas.1920444117</pub-id><pub-id pub-id-type="pmid">32963095</pub-id>
</element-citation>
      </ref>
      <ref id="CR6">
        <element-citation publication-type="journal"><person-group person-group-type="author"><collab>Consortium G</collab></person-group><article-title>The Genotype-Tissue Expression (GTEx) project</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><fpage>580</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1038/ng.2653</pub-id><pub-id pub-id-type="pmid">23715323</pub-id>
</element-citation>
      </ref>
      <ref id="CR7">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De-la-Torre</surname><given-names>P</given-names></name><name><surname>Choudhary</surname><given-names>D</given-names></name><name><surname>Araya-Secchi</surname><given-names>R</given-names></name><name><surname>Narui</surname><given-names>Y</given-names></name><name><surname>Sotomayor</surname><given-names>M</given-names></name></person-group><article-title>A mechanically weak extracellular membrane-adjacent domain induces dimerization of protocadherin-15</article-title><source>Biophys J</source><year>2018</year><volume>115</volume><fpage>2368</fpage><lpage>2385</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2018.11.010</pub-id><pub-id pub-id-type="pmid">30527337</pub-id>
</element-citation>
      </ref>
      <ref id="CR8">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Leva</surname><given-names>F</given-names></name><name><surname>D'Adamo</surname><given-names>P</given-names></name><name><surname>Cubellis</surname><given-names>MV</given-names></name><name><surname>D'Eustacchio</surname><given-names>A</given-names></name><name><surname>Errichiello</surname><given-names>M</given-names></name><name><surname>Saulino</surname><given-names>C</given-names></name><name><surname>Auletta</surname><given-names>G</given-names></name><name><surname>Giannini</surname><given-names>P</given-names></name><name><surname>Donaudy</surname><given-names>F</given-names></name><name><surname>Ciccodicola</surname><given-names>A</given-names></name><name><surname>Gasparini</surname><given-names>P</given-names></name><name><surname>Franze</surname><given-names>A</given-names></name><name><surname>Marciano</surname><given-names>E</given-names></name></person-group><article-title>Identification of a novel mutation in the myosin VIIA motor domain in a family with autosomal dominant hearing loss (DFNA11)</article-title><source>Audiol Neurootol</source><year>2006</year><volume>11</volume><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1159/000091199</pub-id><pub-id pub-id-type="pmid">16449806</pub-id>
</element-citation>
      </ref>
      <ref id="CR9">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiStefano</surname><given-names>MT</given-names></name><name><surname>Hemphill</surname><given-names>SE</given-names></name><name><surname>Oza</surname><given-names>AM</given-names></name><name><surname>Siegert</surname><given-names>RK</given-names></name><name><surname>Grant</surname><given-names>AR</given-names></name><name><surname>Hughes</surname><given-names>MY</given-names></name><name><surname>Cushman</surname><given-names>BJ</given-names></name><name><surname>Azaiez</surname><given-names>H</given-names></name><name><surname>Booth</surname><given-names>KT</given-names></name><name><surname>Chapin</surname><given-names>A</given-names></name><name><surname>Duzkale</surname><given-names>H</given-names></name><name><surname>Matsunaga</surname><given-names>T</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Kenna</surname><given-names>M</given-names></name><name><surname>Schimmenti</surname><given-names>LA</given-names></name><name><surname>Tekin</surname><given-names>M</given-names></name><name><surname>Rehm</surname><given-names>HL</given-names></name><name><surname>Tayoun</surname><given-names>ANA</given-names></name><name><surname>Amr</surname><given-names>SS</given-names></name><collab>ClinGen Hearing Loss Clinical Domain Working G</collab></person-group><article-title>ClinGen expert clinical validity curation of 164 hearing loss gene-disease pairs</article-title><source>Genet Med</source><year>2019</year><volume>21</volume><fpage>2239</fpage><lpage>2247</lpage><pub-id pub-id-type="doi">10.1038/s41436-019-0487-0</pub-id><pub-id pub-id-type="pmid">30894701</pub-id>
</element-citation>
      </ref>
      <ref id="CR10">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downie</surname><given-names>L</given-names></name><name><surname>Halliday</surname><given-names>J</given-names></name><name><surname>Burt</surname><given-names>R</given-names></name><name><surname>Lunke</surname><given-names>S</given-names></name><name><surname>Lynch</surname><given-names>E</given-names></name><name><surname>Martyn</surname><given-names>M</given-names></name><name><surname>Poulakis</surname><given-names>Z</given-names></name><name><surname>Gaff</surname><given-names>C</given-names></name><name><surname>Sung</surname><given-names>V</given-names></name><name><surname>Wake</surname><given-names>M</given-names></name><name><surname>Hunter</surname><given-names>MF</given-names></name><name><surname>Saunders</surname><given-names>K</given-names></name><name><surname>Rose</surname><given-names>E</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Jarmolowicz</surname><given-names>A</given-names></name><name><surname>Phelan</surname><given-names>D</given-names></name><name><surname>Rehm</surname><given-names>HL</given-names></name><name><surname>Melbourne Genomics Health</surname><given-names>A</given-names></name><name><surname>Amor</surname><given-names>DJ</given-names></name></person-group><article-title>Exome sequencing in infants with congenital hearing impairment: a population-based cohort study</article-title><source>Eur J Hum Genet</source><year>2020</year><volume>28</volume><fpage>587</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1038/s41431-019-0553-8</pub-id><pub-id pub-id-type="pmid">31827275</pub-id>
</element-citation>
      </ref>
      <ref id="CR11">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>KP</given-names></name><name><surname>Barry</surname><given-names>C</given-names></name><name><surname>Tran</surname><given-names>AN</given-names></name><name><surname>Traxler</surname><given-names>EA</given-names></name><name><surname>Wannemacher</surname><given-names>KM</given-names></name><name><surname>Tang</surname><given-names>HY</given-names></name><name><surname>Speicher</surname><given-names>KD</given-names></name><name><surname>Blair</surname><given-names>IA</given-names></name><name><surname>Speicher</surname><given-names>DW</given-names></name><name><surname>Grosser</surname><given-names>T</given-names></name><name><surname>Brass</surname><given-names>LF</given-names></name></person-group><article-title>Deciphering the human platelet sheddome</article-title><source>Blood</source><year>2011</year><volume>117</volume><fpage>e15</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-05-283838</pub-id><pub-id pub-id-type="pmid">20962327</pub-id>
</element-citation>
      </ref>
      <ref id="CR12">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>A</given-names></name><name><surname>Mahamdallie</surname><given-names>S</given-names></name><name><surname>Ruark</surname><given-names>E</given-names></name><name><surname>Seal</surname><given-names>S</given-names></name><name><surname>Ramsay</surname><given-names>E</given-names></name><name><surname>Clarke</surname><given-names>M</given-names></name><name><surname>Uddin</surname><given-names>I</given-names></name><name><surname>Wylie</surname><given-names>H</given-names></name><name><surname>Strydom</surname><given-names>A</given-names></name><name><surname>Lunter</surname><given-names>G</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name></person-group><article-title>Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN</article-title><source>Wellcome Open Res</source><year>2016</year><volume>1</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.12688/wellcomeopenres.10069.1</pub-id><pub-id pub-id-type="pmid">28459104</pub-id>
</element-citation>
      </ref>
      <ref id="CR13">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frischmeyer</surname><given-names>PA</given-names></name><name><surname>Dietz</surname><given-names>HC</given-names></name></person-group><article-title>Nonsense-mediated mRNA decay in health and disease</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>1893</fpage><lpage>1900</lpage><pub-id pub-id-type="doi">10.1093/hmg/8.10.1893</pub-id><pub-id pub-id-type="pmid">10469842</pub-id>
</element-citation>
      </ref>
      <ref id="CR14">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiller</surname><given-names>K</given-names></name><name><surname>Grote</surname><given-names>A</given-names></name><name><surname>Scheer</surname><given-names>M</given-names></name><name><surname>Munch</surname><given-names>R</given-names></name><name><surname>Jahn</surname><given-names>D</given-names></name></person-group><article-title>PrediSi: prediction of signal peptides and their cleavage positions</article-title><source>Nucleic Acids Res</source><year>2004</year><volume>32</volume><fpage>W375</fpage><lpage>W379</lpage><pub-id pub-id-type="doi">10.1093/nar/gkh378</pub-id><pub-id pub-id-type="pmid">15215414</pub-id>
</element-citation>
      </ref>
      <ref id="CR15">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogan</surname><given-names>MC</given-names></name><name><surname>Griffin</surname><given-names>MD</given-names></name><name><surname>Rossetti</surname><given-names>S</given-names></name><name><surname>Torres</surname><given-names>VE</given-names></name><name><surname>Ward</surname><given-names>CJ</given-names></name><name><surname>Harris</surname><given-names>PC</given-names></name></person-group><article-title>PKHDL1, a homolog of the autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte expression</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><fpage>685</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddg068</pub-id><pub-id pub-id-type="pmid">12620974</pub-id>
</element-citation>
      </ref>
      <ref id="CR16">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ioannidis</surname><given-names>NM</given-names></name><name><surname>Rothstein</surname><given-names>JH</given-names></name><name><surname>Pejaver</surname><given-names>V</given-names></name><name><surname>Middha</surname><given-names>S</given-names></name><name><surname>McDonnell</surname><given-names>SK</given-names></name><name><surname>Baheti</surname><given-names>S</given-names></name><name><surname>Musolf</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Holzinger</surname><given-names>E</given-names></name><name><surname>Karyadi</surname><given-names>D</given-names></name><name><surname>Cannon-Albright</surname><given-names>LA</given-names></name><name><surname>Teerlink</surname><given-names>CC</given-names></name><name><surname>Stanford</surname><given-names>JL</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Cooney</surname><given-names>KA</given-names></name><name><surname>Lange</surname><given-names>EM</given-names></name><name><surname>Schleutker</surname><given-names>J</given-names></name><name><surname>Carpten</surname><given-names>JD</given-names></name><name><surname>Powell</surname><given-names>IJ</given-names></name><name><surname>Cussenot</surname><given-names>O</given-names></name><name><surname>Cancel-Tassin</surname><given-names>G</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name><name><surname>MacInnis</surname><given-names>RJ</given-names></name><name><surname>Maier</surname><given-names>C</given-names></name><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Wiklund</surname><given-names>F</given-names></name><name><surname>Catalona</surname><given-names>WJ</given-names></name><name><surname>Foulkes</surname><given-names>WD</given-names></name><name><surname>Mandal</surname><given-names>D</given-names></name><name><surname>Eeles</surname><given-names>RA</given-names></name><name><surname>Kote-Jarai</surname><given-names>Z</given-names></name><name><surname>Bustamante</surname><given-names>CD</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Ostrander</surname><given-names>EA</given-names></name><name><surname>Bailey-Wilson</surname><given-names>JE</given-names></name><name><surname>Radivojac</surname><given-names>P</given-names></name><name><surname>Thibodeau</surname><given-names>SN</given-names></name><name><surname>Whittemore</surname><given-names>AS</given-names></name><name><surname>Sieh</surname><given-names>W</given-names></name></person-group><article-title>REVEL: an ensemble method for predicting the pathogenicity of rare missense variants</article-title><source>Am J Hum Genet</source><year>2016</year><volume>99</volume><fpage>877</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2016.08.016</pub-id><pub-id pub-id-type="pmid">27666373</pub-id>
</element-citation>
      </ref>
      <ref id="CR17">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaganathan</surname><given-names>K</given-names></name><name><surname>Kyriazopoulou Panagiotopoulou</surname><given-names>S</given-names></name><name><surname>McRae</surname><given-names>JF</given-names></name><name><surname>Darbandi</surname><given-names>SF</given-names></name><name><surname>Knowles</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>YI</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Arbelaez</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>W</given-names></name><name><surname>Schwartz</surname><given-names>GB</given-names></name><name><surname>Chow</surname><given-names>ED</given-names></name><name><surname>Kanterakis</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Kia</surname><given-names>A</given-names></name><name><surname>Batzoglou</surname><given-names>S</given-names></name><name><surname>Sanders</surname><given-names>SJ</given-names></name><name><surname>Farh</surname><given-names>KK</given-names></name></person-group><article-title>Predicting splicing from primary sequence with deep learning</article-title><source>Cell</source><year>2019</year><volume>176</volume><fpage>535</fpage><lpage>548.e24</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.12.015</pub-id><pub-id pub-id-type="pmid">30661751</pub-id>
</element-citation>
      </ref>
      <ref id="CR18">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiganesh</surname><given-names>A</given-names></name><name><surname>De-la-Torre</surname><given-names>P</given-names></name><name><surname>Patel</surname><given-names>AA</given-names></name><name><surname>Termine</surname><given-names>DJ</given-names></name><name><surname>Velez-Cortes</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Sotomayor</surname><given-names>M</given-names></name></person-group><article-title>Zooming in on Cadherin-23: structural diversity and potential mechanisms of inherited deafness</article-title><source>Structure</source><year>2018</year><volume>26</volume><fpage>1210</fpage><lpage>1225.e4</lpage><pub-id pub-id-type="doi">10.1016/j.str.2018.06.003</pub-id><pub-id pub-id-type="pmid">30033219</pub-id>
</element-citation>
      </ref>
      <ref id="CR19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kafita</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nkhoma</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dzobo</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sinkala</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Shedding light on the dark genome: insights into the genetic, CRISPR-based, and pharmacological dependencies of human cancers and disease aggressiveness</article-title>
          <source>bioRxiv</source>
          <year>2023</year>
          <pub-id pub-id-type="doi">10.1101/2023.08.15.552589</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>Y</given-names></name><name><surname>Nakano</surname><given-names>A</given-names></name><name><surname>Arimoto</surname><given-names>Y</given-names></name><name><surname>Nara</surname><given-names>K</given-names></name><name><surname>Mutai</surname><given-names>H</given-names></name><name><surname>Matsunaga</surname><given-names>T</given-names></name></person-group><article-title>The first sporadic case of DFNA11 identified by next-generation sequencing</article-title><source>Int J Pediatr Otorhinolaryngol</source><year>2017</year><volume>100</volume><fpage>183</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.ijporl.2017.07.007</pub-id><pub-id pub-id-type="pmid">28802369</pub-id>
</element-citation>
      </ref>
      <ref id="CR21">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Francioli</surname><given-names>LC</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Cummings</surname><given-names>BB</given-names></name><name><surname>Alfoldi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Collins</surname><given-names>RL</given-names></name><name><surname>Laricchia</surname><given-names>KM</given-names></name><name><surname>Ganna</surname><given-names>A</given-names></name><name><surname>Birnbaum</surname><given-names>DP</given-names></name><name><surname>Gauthier</surname><given-names>LD</given-names></name><name><surname>Brand</surname><given-names>H</given-names></name><name><surname>Solomonson</surname><given-names>M</given-names></name><name><surname>Watts</surname><given-names>NA</given-names></name><name><surname>Rhodes</surname><given-names>D</given-names></name><name><surname>Singer-Berk</surname><given-names>M</given-names></name><name><surname>England</surname><given-names>EM</given-names></name><name><surname>Seaby</surname><given-names>EG</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Walters</surname><given-names>RK</given-names></name><name><surname>Tashman</surname><given-names>K</given-names></name><name><surname>Farjoun</surname><given-names>Y</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Poterba</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Seed</surname><given-names>C</given-names></name><name><surname>Whiffin</surname><given-names>N</given-names></name><name><surname>Chong</surname><given-names>JX</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Pierce-Hoffman</surname><given-names>E</given-names></name><name><surname>Zappala</surname><given-names>Z</given-names></name><name><surname>O'Donnell-Luria</surname><given-names>AH</given-names></name><name><surname>Minikel</surname><given-names>EV</given-names></name><name><surname>Weisburd</surname><given-names>B</given-names></name><name><surname>Lek</surname><given-names>M</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Vittal</surname><given-names>C</given-names></name><name><surname>Armean</surname><given-names>IM</given-names></name><name><surname>Bergelson</surname><given-names>L</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Connolly</surname><given-names>KM</given-names></name><name><surname>Covarrubias</surname><given-names>M</given-names></name><name><surname>Donnelly</surname><given-names>S</given-names></name><name><surname>Ferriera</surname><given-names>S</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Gentry</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Jeandet</surname><given-names>T</given-names></name><name><surname>Kaplan</surname><given-names>D</given-names></name><name><surname>Llanwarne</surname><given-names>C</given-names></name><name><surname>Munshi</surname><given-names>R</given-names></name><name><surname>Novod</surname><given-names>S</given-names></name><name><surname>Petrillo</surname><given-names>N</given-names></name><name><surname>Roazen</surname><given-names>D</given-names></name><name><surname>Ruano-Rubio</surname><given-names>V</given-names></name><name><surname>Saltzman</surname><given-names>A</given-names></name><name><surname>Schleicher</surname><given-names>M</given-names></name><name><surname>Soto</surname><given-names>J</given-names></name><name><surname>Tibbetts</surname><given-names>K</given-names></name><name><surname>Tolonen</surname><given-names>C</given-names></name><name><surname>Wade</surname><given-names>G</given-names></name><name><surname>Talkowski</surname><given-names>ME</given-names></name><name><surname>Genome Aggregation Database</surname><given-names>C</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name></person-group><article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title><source>Nature</source><year>2020</year><volume>581</volume><fpage>434</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2308-7</pub-id><pub-id pub-id-type="pmid">32461654</pub-id>
</element-citation>
      </ref>
      <ref id="CR22">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kearse</surname><given-names>M</given-names></name><name><surname>Moir</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>A</given-names></name><name><surname>Stones-Havas</surname><given-names>S</given-names></name><name><surname>Cheung</surname><given-names>M</given-names></name><name><surname>Sturrock</surname><given-names>S</given-names></name><name><surname>Buxton</surname><given-names>S</given-names></name><name><surname>Cooper</surname><given-names>A</given-names></name><name><surname>Markowitz</surname><given-names>S</given-names></name><name><surname>Duran</surname><given-names>C</given-names></name><name><surname>Thierer</surname><given-names>T</given-names></name><name><surname>Ashton</surname><given-names>B</given-names></name><name><surname>Meintjes</surname><given-names>P</given-names></name><name><surname>Drummond</surname><given-names>A</given-names></name></person-group><article-title>Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data</article-title><source>Bioinformatics</source><year>2012</year><volume>28</volume><fpage>1647</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts199</pub-id><pub-id pub-id-type="pmid">22543367</pub-id>
</element-citation>
      </ref>
      <ref id="CR23">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krieger</surname><given-names>F</given-names></name><name><surname>Moglich</surname><given-names>A</given-names></name><name><surname>Kiefhaber</surname><given-names>T</given-names></name></person-group><article-title>Effect of proline and glycine residues on dynamics and barriers of loop formation in polypeptide chains</article-title><source>J Am Chem Soc</source><year>2005</year><volume>127</volume><fpage>3346</fpage><lpage>3352</lpage><pub-id pub-id-type="doi">10.1021/ja042798i</pub-id><pub-id pub-id-type="pmid">15755151</pub-id>
</element-citation>
      </ref>
      <ref id="CR24">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krumm</surname><given-names>N</given-names></name><name><surname>Sudmant</surname><given-names>PH</given-names></name><name><surname>Ko</surname><given-names>A</given-names></name><name><surname>O'Roak</surname><given-names>BJ</given-names></name><name><surname>Malig</surname><given-names>M</given-names></name><name><surname>Coe</surname><given-names>BP</given-names></name><collab>Project NES</collab><name><surname>Quinlan</surname><given-names>AR</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name></person-group><article-title>Copy number variation detection and genotyping from exome sequence data</article-title><source>Genome Res</source><year>2012</year><volume>22</volume><fpage>1525</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1101/gr.138115.112</pub-id><pub-id pub-id-type="pmid">22585873</pub-id>
</element-citation>
      </ref>
      <ref id="CR25">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larkin</surname><given-names>MA</given-names></name><name><surname>Blackshields</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>NP</given-names></name><name><surname>Chenna</surname><given-names>R</given-names></name><name><surname>McGettigan</surname><given-names>PA</given-names></name><name><surname>McWilliam</surname><given-names>H</given-names></name><name><surname>Valentin</surname><given-names>F</given-names></name><name><surname>Wallace</surname><given-names>IM</given-names></name><name><surname>Wilm</surname><given-names>A</given-names></name><name><surname>Lopez</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>JD</given-names></name><name><surname>Gibson</surname><given-names>TJ</given-names></name><name><surname>Higgins</surname><given-names>DG</given-names></name></person-group><article-title>Clustal W and Clustal X version 2.0</article-title><source>Bioinformatics</source><year>2007</year><volume>23</volume><fpage>2947</fpage><lpage>2948</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btm404</pub-id><pub-id pub-id-type="pmid">17846036</pub-id>
</element-citation>
      </ref>
      <ref id="CR26">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letunic</surname><given-names>I</given-names></name><name><surname>Khedkar</surname><given-names>S</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name></person-group><article-title>SMART: recent updates, new developments and status in 2020</article-title><source>Nucleic Acids Res</source><year>2021</year><volume>49</volume><fpage>D458</fpage><lpage>D460</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa937</pub-id><pub-id pub-id-type="pmid">33104802</pub-id>
</element-citation>
      </ref>
      <ref id="CR27">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>MA</given-names></name><name><surname>Schulte</surname><given-names>J</given-names></name><name><surname>Matthews</surname><given-names>L</given-names></name><name><surname>Vaden</surname><given-names>KI</given-names></name><name><surname>Steves</surname><given-names>CJ</given-names></name><name><surname>Williams</surname><given-names>FMK</given-names></name><name><surname>Schulte</surname><given-names>BA</given-names></name><name><surname>Dubno</surname><given-names>JR</given-names></name><name><surname>Steel</surname><given-names>KP</given-names></name></person-group><article-title>Accurate phenotypic classification and exome sequencing allow identification of novel genes and variants associated with adult-onset hearing loss</article-title><source>medRxiv</source><year>2023</year><pub-id pub-id-type="doi">10.1101/2023.04.27.23289040</pub-id><pub-id pub-id-type="pmid">38234770</pub-id>
</element-citation>
      </ref>
      <ref id="CR28">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lezirovitz</surname><given-names>K</given-names></name><name><surname>Mingroni-Netto</surname><given-names>RC</given-names></name></person-group><article-title>Genetic etiology of non-syndromic hearing loss in Latin America</article-title><source>Hum Genet</source><year>2022</year><volume>141</volume><fpage>539</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1007/s00439-021-02354-4</pub-id><pub-id pub-id-type="pmid">34652575</pub-id>
</element-citation>
      </ref>
      <ref id="CR29">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Mysickova</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Kalscheuer</surname><given-names>V</given-names></name><name><surname>Vingron</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>SA</given-names></name></person-group><article-title>Modeling read counts for CNV detection in exome sequencing data</article-title><source>Stat Appl Genet Mol Biol</source><year>2011</year><pub-id pub-id-type="doi">10.2202/1544-6115.1732</pub-id><pub-id pub-id-type="pmid">23089826</pub-id>
</element-citation>
      </ref>
      <ref id="CR30">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makrogkikas</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>RK</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name></person-group><article-title>A conserved function of Pkhd1l1, a mammalian hair cell stereociliary coat protein, in regulating hearing in zebrafish</article-title><source>J Neurogenet</source><year>2023</year><pub-id pub-id-type="doi">10.1080/01677063.2023.2187792</pub-id><pub-id pub-id-type="pmid">36960824</pub-id>
</element-citation>
      </ref>
      <ref id="CR31">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maynard</surname><given-names>DM</given-names></name><name><surname>Heijnen</surname><given-names>HF</given-names></name><name><surname>Horne</surname><given-names>MK</given-names></name><name><surname>White</surname><given-names>JG</given-names></name><name><surname>Gahl</surname><given-names>WA</given-names></name></person-group><article-title>Proteomic analysis of platelet alpha-granules using mass spectrometry</article-title><source>J Thromb Haemost</source><year>2007</year><volume>5</volume><fpage>1945</fpage><lpage>1955</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2007.02690.x</pub-id><pub-id pub-id-type="pmid">17723134</pub-id>
</element-citation>
      </ref>
      <ref id="CR32">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalski</surname><given-names>N</given-names></name><name><surname>Petit</surname><given-names>C</given-names></name></person-group><article-title>Genetics of auditory mechano-electrical transduction</article-title><source>Pflugers Arch</source><year>2015</year><volume>467</volume><fpage>49</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s00424-014-1552-9</pub-id><pub-id pub-id-type="pmid">24957570</pub-id>
</element-citation>
      </ref>
      <ref id="CR33">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirdita</surname><given-names>M</given-names></name><name><surname>Schutze</surname><given-names>K</given-names></name><name><surname>Moriwaki</surname><given-names>Y</given-names></name><name><surname>Heo</surname><given-names>L</given-names></name><name><surname>Ovchinnikov</surname><given-names>S</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name></person-group><article-title>ColabFold: making protein folding accessible to all</article-title><source>Nat Methods</source><year>2022</year><volume>19</volume><fpage>679</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/s41592-022-01488-1</pub-id><pub-id pub-id-type="pmid">35637307</pub-id>
</element-citation>
      </ref>
      <ref id="CR34">
        <mixed-citation publication-type="other">Mucha BE, Hennekam RCM, Sisodiya S, Campeau PM (1993) TBC1D24-related disorders. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A (eds) GeneReviews((R)), Seattle (WA)</mixed-citation>
      </ref>
      <ref id="CR35">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>PC</given-names></name><name><surname>Henikoff</surname><given-names>S</given-names></name></person-group><article-title>Predicting deleterious amino acid substitutions</article-title><source>Genome Res</source><year>2001</year><volume>11</volume><fpage>863</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1101/gr.176601</pub-id><pub-id pub-id-type="pmid">11337480</pub-id>
</element-citation>
      </ref>
      <ref id="CR36">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>M</given-names></name><name><surname>McGrath</surname><given-names>M</given-names></name><name><surname>Sammon</surname><given-names>D</given-names></name><name><surname>Gardner</surname><given-names>S</given-names></name><name><surname>Morgan</surname><given-names>RM</given-names></name><name><surname>Di Maio</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Bubeck</surname><given-names>D</given-names></name><name><surname>Hohenester</surname><given-names>E</given-names></name></person-group><article-title>Structure of the transmembrane protein 2 (TMEM2) ectodomain and its apparent lack of hyaluronidase activity</article-title><source>Wellcome Open Res</source><year>2023</year><volume>8</volume><fpage>76</fpage><pub-id pub-id-type="doi">10.12688/wellcomeopenres.18937.2</pub-id><pub-id pub-id-type="pmid">37234743</pub-id>
</element-citation>
      </ref>
      <ref id="CR37">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oza</surname><given-names>AM</given-names></name><name><surname>DiStefano</surname><given-names>MT</given-names></name><name><surname>Hemphill</surname><given-names>SE</given-names></name><name><surname>Cushman</surname><given-names>BJ</given-names></name><name><surname>Grant</surname><given-names>AR</given-names></name><name><surname>Siegert</surname><given-names>RK</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Chapin</surname><given-names>A</given-names></name><name><surname>Boczek</surname><given-names>NJ</given-names></name><name><surname>Schimmenti</surname><given-names>LA</given-names></name><name><surname>Murry</surname><given-names>JB</given-names></name><name><surname>Hasadsri</surname><given-names>L</given-names></name><name><surname>Nara</surname><given-names>K</given-names></name><name><surname>Kenna</surname><given-names>M</given-names></name><name><surname>Booth</surname><given-names>KT</given-names></name><name><surname>Azaiez</surname><given-names>H</given-names></name><name><surname>Griffith</surname><given-names>A</given-names></name><name><surname>Avraham</surname><given-names>KB</given-names></name><name><surname>Kremer</surname><given-names>H</given-names></name><name><surname>Rehm</surname><given-names>HL</given-names></name><name><surname>Amr</surname><given-names>SS</given-names></name><name><surname>Abou Tayoun</surname><given-names>AN</given-names></name><collab>ClinGen Hearing Loss Clinical Domain Working</collab></person-group><article-title>Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing loss</article-title><source>Hum Mutat</source><year>2018</year><volume>39</volume><fpage>1593</fpage><lpage>1613</lpage><pub-id pub-id-type="doi">10.1002/humu.23630</pub-id><pub-id pub-id-type="pmid">30311386</pub-id>
</element-citation>
      </ref>
      <ref id="CR38">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>J</given-names></name><name><surname>Redfield</surname><given-names>S</given-names></name><name><surname>Oza</surname><given-names>A</given-names></name><name><surname>Rouse</surname><given-names>S</given-names></name><name><surname>Stewart</surname><given-names>C</given-names></name><name><surname>Khela</surname><given-names>H</given-names></name><name><surname>Srinivasan</surname><given-names>T</given-names></name><name><surname>Albano</surname><given-names>V</given-names></name><name><surname>Shearer</surname><given-names>E</given-names></name><name><surname>Kenna</surname><given-names>M</given-names></name></person-group><article-title>Exome sequencing expands the genetic diagnostic spectrum for pediatric hearing loss</article-title><source>Laryngoscope</source><year>2023</year><volume>133</volume><fpage>2417</fpage><lpage>2424</lpage><pub-id pub-id-type="doi">10.1002/lary.30507</pub-id><pub-id pub-id-type="pmid">36515421</pub-id>
</element-citation>
      </ref>
      <ref id="CR39">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petit</surname><given-names>C</given-names></name><name><surname>Richardson</surname><given-names>GP</given-names></name></person-group><article-title>Linking genes underlying deafness to hair-bundle development and function</article-title><source>Nat Neurosci</source><year>2009</year><volume>12</volume><fpage>703</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1038/nn.2330</pub-id><pub-id pub-id-type="pmid">19471269</pub-id>
</element-citation>
      </ref>
      <ref id="CR40">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plagnol</surname><given-names>V</given-names></name><name><surname>Curtis</surname><given-names>J</given-names></name><name><surname>Epstein</surname><given-names>M</given-names></name><name><surname>Mok</surname><given-names>KY</given-names></name><name><surname>Stebbings</surname><given-names>E</given-names></name><name><surname>Grigoriadou</surname><given-names>S</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Hambleton</surname><given-names>S</given-names></name><name><surname>Burns</surname><given-names>SO</given-names></name><name><surname>Thrasher</surname><given-names>AJ</given-names></name><name><surname>Kumararatne</surname><given-names>D</given-names></name><name><surname>Doffinger</surname><given-names>R</given-names></name><name><surname>Nejentsev</surname><given-names>S</given-names></name></person-group><article-title>A robust model for read count data in exome sequencing experiments and implications for copy number variant calling</article-title><source>Bioinformatics</source><year>2012</year><volume>28</volume><fpage>2747</fpage><lpage>2754</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts526</pub-id><pub-id pub-id-type="pmid">22942019</pub-id>
</element-citation>
      </ref>
      <ref id="CR41">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redfield</surname><given-names>SE</given-names></name><name><surname>De-la-Torre</surname><given-names>P</given-names></name><name><surname>Zamani</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>H</given-names></name><name><surname>Morris</surname><given-names>T</given-names></name><name><surname>Shariati</surname><given-names>G</given-names></name><name><surname>Karimi</surname><given-names>M</given-names></name><name><surname>Kenna</surname><given-names>MA</given-names></name><name><surname>Seo</surname><given-names>GH</given-names></name><name><surname>Naz</surname><given-names>S</given-names></name><name><surname>Galehdari</surname><given-names>H</given-names></name><name><surname>Indzhykulian</surname><given-names>AA</given-names></name><name><surname>Shearer</surname><given-names>AE</given-names></name><name><surname>Vona</surname><given-names>B</given-names></name></person-group><article-title>PKHD1L1, a gene involved in the stereociliary coat causes autosomal recessive nonsyndromic hearing loss</article-title><source>medRxiv</source><year>2023</year><pub-id pub-id-type="doi">10.1101/2023.10.08.23296081</pub-id><pub-id pub-id-type="pmid">37873491</pub-id>
</element-citation>
      </ref>
      <ref id="CR42">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehman</surname><given-names>AU</given-names></name><name><surname>Friedman</surname><given-names>TB</given-names></name><name><surname>Griffith</surname><given-names>AJ</given-names></name></person-group><article-title>Unresolved questions regarding human hereditary deafness</article-title><source>Oral Dis</source><year>2017</year><volume>23</volume><fpage>551</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1111/odi.12516</pub-id><pub-id pub-id-type="pmid">27259978</pub-id>
</element-citation>
      </ref>
      <ref id="CR43">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rentzsch</surname><given-names>P</given-names></name><name><surname>Witten</surname><given-names>D</given-names></name><name><surname>Cooper</surname><given-names>GM</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Kircher</surname><given-names>M</given-names></name></person-group><article-title>CADD: predicting the deleteriousness of variants throughout the human genome</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><fpage>D886</fpage><lpage>D894</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1016</pub-id><pub-id pub-id-type="pmid">30371827</pub-id>
</element-citation>
      </ref>
      <ref id="CR44">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockowitz</surname><given-names>S</given-names></name><name><surname>LeCompte</surname><given-names>N</given-names></name><name><surname>Carmack</surname><given-names>M</given-names></name><name><surname>Quitadamo</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Knight</surname><given-names>D</given-names></name><name><surname>Sexton</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name><name><surname>Sheidley</surname><given-names>B</given-names></name><name><surname>Field</surname><given-names>M</given-names></name><name><surname>Holm</surname><given-names>IA</given-names></name><name><surname>Brownstein</surname><given-names>CA</given-names></name><name><surname>Agrawal</surname><given-names>PB</given-names></name><name><surname>Kornetsky</surname><given-names>S</given-names></name><name><surname>Poduri</surname><given-names>A</given-names></name><name><surname>Snapper</surname><given-names>SB</given-names></name><name><surname>Beggs</surname><given-names>AH</given-names></name><name><surname>Yu</surname><given-names>TW</given-names></name><name><surname>Williams</surname><given-names>DA</given-names></name><name><surname>Sliz</surname><given-names>P</given-names></name></person-group><article-title>Children's rare disease cohorts: an integrative research and clinical genomics initiative</article-title><source>NPJ Genom Med</source><year>2020</year><volume>5</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1038/s41525-020-0137-0</pub-id><pub-id pub-id-type="pmid">32655885</pub-id>
</element-citation>
      </ref>
      <ref id="CR45">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouse</surname><given-names>SL</given-names></name><name><surname>Florentine</surname><given-names>MM</given-names></name><name><surname>Taketa</surname><given-names>E</given-names></name><name><surname>Chan</surname><given-names>DK</given-names></name></person-group><article-title>Racial and ethnic disparities in genetic testing for hearing loss: a systematic review and synthesis</article-title><source>Hum Genet</source><year>2022</year><volume>141</volume><fpage>485</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1007/s00439-021-02335-7</pub-id><pub-id pub-id-type="pmid">34494120</pub-id>
</element-citation>
      </ref>
      <ref id="CR46">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santi</surname><given-names>PA</given-names></name><name><surname>Anderson</surname><given-names>CB</given-names></name></person-group><article-title>A newly identified surface coat on cochlear hair cells</article-title><source>Hear Res</source><year>1987</year><volume>27</volume><fpage>47</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/0378-5955(87)90025-6</pub-id><pub-id pub-id-type="pmid">3583936</pub-id>
</element-citation>
      </ref>
      <ref id="CR47">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><name><surname>Mizutani</surname><given-names>Y</given-names></name><name><surname>Mizukami</surname><given-names>Y</given-names></name><name><surname>Higashiyama</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name></person-group><article-title>Human TMEM2 is not a catalytic hyaluronidase, but a regulator of hyaluronan metabolism via HYBID (KIAA1199/CEMIP) and HAS2 expression</article-title><source>J Biol Chem</source><year>2023</year><volume>299</volume><fpage>104826</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2023.104826</pub-id><pub-id pub-id-type="pmid">37196767</pub-id>
</element-citation>
      </ref>
      <ref id="CR48">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>JM</given-names></name><name><surname>Cooper</surname><given-names>DN</given-names></name><name><surname>Schuelke</surname><given-names>M</given-names></name><name><surname>Seelow</surname><given-names>D</given-names></name></person-group><article-title>MutationTaster2: mutation prediction for the deep-sequencing age</article-title><source>Nat Methods</source><year>2014</year><volume>11</volume><fpage>361</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2890</pub-id><pub-id pub-id-type="pmid">24681721</pub-id>
</element-citation>
      </ref>
      <ref id="CR49">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shearer</surname><given-names>AE</given-names></name><name><surname>Smith</surname><given-names>RJ</given-names></name></person-group><article-title>Massively parallel sequencing for genetic diagnosis of hearing loss: the new standard of care</article-title><source>Otolaryngol Head Neck Surg</source><year>2015</year><volume>153</volume><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1177/0194599815591156</pub-id><pub-id pub-id-type="pmid">26084827</pub-id>
</element-citation>
      </ref>
      <ref id="CR50">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shihab</surname><given-names>HA</given-names></name><name><surname>Gough</surname><given-names>J</given-names></name><name><surname>Mort</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>DN</given-names></name><name><surname>Day</surname><given-names>IN</given-names></name><name><surname>Gaunt</surname><given-names>TR</given-names></name></person-group><article-title>Ranking non-synonymous single nucleotide polymorphisms based on disease concepts</article-title><source>Hum Genomics</source><year>2014</year><volume>8</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/1479-7364-8-11</pub-id><pub-id pub-id-type="pmid">24980617</pub-id>
</element-citation>
      </ref>
      <ref id="CR51">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slepecky</surname><given-names>N</given-names></name><name><surname>Chamberlain</surname><given-names>SC</given-names></name></person-group><article-title>The cell coat of inner ear sensory and supporting cells as demonstrated by ruthenium red</article-title><source>Hear Res</source><year>1985</year><volume>17</volume><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/0378-5955(85)90072-3</pub-id><pub-id pub-id-type="pmid">2410399</pub-id>
</element-citation>
      </ref>
      <ref id="CR52">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sloan-Heggen</surname><given-names>CM</given-names></name><name><surname>Bierer</surname><given-names>AO</given-names></name><name><surname>Shearer</surname><given-names>AE</given-names></name><name><surname>Kolbe</surname><given-names>DL</given-names></name><name><surname>Nishimura</surname><given-names>CJ</given-names></name><name><surname>Frees</surname><given-names>KL</given-names></name><name><surname>Ephraim</surname><given-names>SS</given-names></name><name><surname>Shibata</surname><given-names>SB</given-names></name><name><surname>Booth</surname><given-names>KT</given-names></name><name><surname>Campbell</surname><given-names>CA</given-names></name><name><surname>Ranum</surname><given-names>PT</given-names></name><name><surname>Weaver</surname><given-names>AE</given-names></name><name><surname>Black-Ziegelbein</surname><given-names>EA</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Azaiez</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>RJH</given-names></name></person-group><article-title>Comprehensive genetic testing in the clinical evaluation of 1119 patients with hearing loss</article-title><source>Hum Genet</source><year>2016</year><volume>135</volume><fpage>441</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1007/s00439-016-1648-8</pub-id><pub-id pub-id-type="pmid">26969326</pub-id>
</element-citation>
      </ref>
      <ref id="CR53">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RJ</given-names></name><name><surname>Bale</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>White</surname><given-names>KR</given-names></name></person-group><article-title>Sensorineural hearing loss in children</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>879</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)71047-3</pub-id><pub-id pub-id-type="pmid">15752533</pub-id>
</element-citation>
      </ref>
      <ref id="CR54">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vona</surname><given-names>B</given-names></name><name><surname>Hofrichter</surname><given-names>MA</given-names></name><name><surname>Neuner</surname><given-names>C</given-names></name><name><surname>Schroder</surname><given-names>J</given-names></name><name><surname>Gehrig</surname><given-names>A</given-names></name><name><surname>Hennermann</surname><given-names>JB</given-names></name><name><surname>Kraus</surname><given-names>F</given-names></name><name><surname>Shehata-Dieler</surname><given-names>W</given-names></name><name><surname>Klopocki</surname><given-names>E</given-names></name><name><surname>Nanda</surname><given-names>I</given-names></name><name><surname>Haaf</surname><given-names>T</given-names></name></person-group><article-title>DFNB16 is a frequent cause of congenital hearing impairment: implementation of STRC mutation analysis in routine diagnostics</article-title><source>Clin Genet</source><year>2015</year><volume>87</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/cge.12332</pub-id><pub-id pub-id-type="pmid">26011646</pub-id>
</element-citation>
      </ref>
      <ref id="CR55">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vona</surname><given-names>B</given-names></name><name><surname>Mazaheri</surname><given-names>N</given-names></name><name><surname>Lin</surname><given-names>SJ</given-names></name><name><surname>Dunbar</surname><given-names>LA</given-names></name><name><surname>Maroofian</surname><given-names>R</given-names></name><name><surname>Azaiez</surname><given-names>H</given-names></name><name><surname>Booth</surname><given-names>KT</given-names></name><name><surname>Vitry</surname><given-names>S</given-names></name><name><surname>Rad</surname><given-names>A</given-names></name><name><surname>Ruschendorf</surname><given-names>F</given-names></name><name><surname>Varshney</surname><given-names>P</given-names></name><name><surname>Fowler</surname><given-names>B</given-names></name><name><surname>Beetz</surname><given-names>C</given-names></name><name><surname>Alagramam</surname><given-names>KN</given-names></name><name><surname>Murphy</surname><given-names>D</given-names></name><name><surname>Shariati</surname><given-names>G</given-names></name><name><surname>Sedaghat</surname><given-names>A</given-names></name><name><surname>Houlden</surname><given-names>H</given-names></name><name><surname>Petree</surname><given-names>C</given-names></name><name><surname>VijayKumar</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>RJH</given-names></name><name><surname>Haaf</surname><given-names>T</given-names></name><name><surname>El-Amraoui</surname><given-names>A</given-names></name><name><surname>Bowl</surname><given-names>MR</given-names></name><name><surname>Varshney</surname><given-names>GK</given-names></name><name><surname>Galehdari</surname><given-names>H</given-names></name></person-group><article-title>A biallelic variant in CLRN2 causes non-syndromic hearing loss in humans</article-title><source>Hum Genet</source><year>2021</year><volume>140</volume><fpage>915</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1007/s00439-020-02254-z</pub-id><pub-id pub-id-type="pmid">33496845</pub-id>
</element-citation>
      </ref>
      <ref id="CR56">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Bai</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>F</given-names></name></person-group><article-title>Role and mechanism of benzo[a]pyrene in the transformation of chronic obstructive pulmonary disease into lung adenocarcinoma</article-title><source>J Cancer Res Clin Oncol</source><year>2023</year><volume>149</volume><fpage>4741</fpage><lpage>4760</lpage><pub-id pub-id-type="doi">10.1007/s00432-022-04353-y</pub-id><pub-id pub-id-type="pmid">36229541</pub-id>
</element-citation>
      </ref>
      <ref id="CR57">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiel</surname><given-names>L</given-names></name><name><surname>Baakman</surname><given-names>C</given-names></name><name><surname>Gilissen</surname><given-names>D</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name><name><surname>Vriend</surname><given-names>G</given-names></name><name><surname>Gilissen</surname><given-names>C</given-names></name></person-group><article-title>MetaDome: pathogenicity analysis of genetic variants through aggregation of homologous human protein domains</article-title><source>Hum Mutat</source><year>2019</year><volume>40</volume><fpage>1030</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1002/humu.23798</pub-id><pub-id pub-id-type="pmid">31116477</pub-id>
</element-citation>
      </ref>
      <ref id="CR58">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Ivanchenko</surname><given-names>MV</given-names></name><name><surname>Al Jandal</surname><given-names>H</given-names></name><name><surname>Cicconet</surname><given-names>M</given-names></name><name><surname>Indzhykulian</surname><given-names>AA</given-names></name><name><surname>Corey</surname><given-names>DP</given-names></name></person-group><article-title>PKHD1L1 is a coat protein of hair-cell stereocilia and is required for normal hearing</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>3801</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-11712-w</pub-id><pub-id pub-id-type="pmid">31444330</pub-id>
</element-citation>
      </ref>
      <ref id="CR59">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Tobisawa</surname><given-names>Y</given-names></name><name><surname>Inubushi</surname><given-names>T</given-names></name><name><surname>Irie</surname><given-names>F</given-names></name><name><surname>Ohyama</surname><given-names>C</given-names></name><name><surname>Yamaguchi</surname><given-names>Y</given-names></name></person-group><article-title>A mammalian homolog of the zebrafish transmembrane protein 2 (TMEM2) is the long-sought-after cell-surface hyaluronidase</article-title><source>J Biol Chem</source><year>2017</year><volume>292</volume><fpage>7304</fpage><lpage>7313</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.770149</pub-id><pub-id pub-id-type="pmid">28246172</pub-id>
</element-citation>
      </ref>
      <ref id="CR60">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Pang</surname><given-names>Q</given-names></name><name><surname>Hua</surname><given-names>M</given-names></name><name><surname>Huangfu</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name></person-group><article-title>Excavation of diagnostic biomarkers and construction of prognostic model for clear cell renal cell carcinoma based on urine proteomics</article-title><source>Front Oncol</source><year>2023</year><volume>13</volume><fpage>1170567</fpage><pub-id pub-id-type="doi">10.3389/fonc.2023.1170567</pub-id><pub-id pub-id-type="pmid">37260987</pub-id>
</element-citation>
      </ref>
      <ref id="CR61">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Nagaoka</surname><given-names>A</given-names></name><name><surname>Kusaka-Kikushima</surname><given-names>A</given-names></name><name><surname>Tobiishi</surname><given-names>M</given-names></name><name><surname>Kawabata</surname><given-names>K</given-names></name><name><surname>Sayo</surname><given-names>T</given-names></name><name><surname>Sakai</surname><given-names>S</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name><name><surname>Enomoto</surname><given-names>H</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name></person-group><article-title>KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding protein involved in hyaluronan depolymerization</article-title><source>Proc Natl Acad Sci USA</source><year>2013</year><volume>110</volume><fpage>5612</fpage><lpage>5617</lpage><pub-id pub-id-type="doi">10.1073/pnas.1215432110</pub-id><pub-id pub-id-type="pmid">23509262</pub-id>
</element-citation>
      </ref>
      <ref id="CR62">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Deficit of PKHD1L1 in the dentate gyrus increases seizure susceptibility in mice</article-title><source>Hum Mol Genet</source><year>2023</year><volume>32</volume><fpage>506</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddac220</pub-id><pub-id pub-id-type="pmid">36067019</pub-id>
</element-citation>
      </ref>
      <ref id="CR63">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name></person-group><article-title>A novel splicing variant in the TMC1 gene causes non-syndromic hearing loss in a Chinese family</article-title><source>Chin Med J (engl)</source><year>2022</year><volume>135</volume><fpage>2631</fpage><lpage>2633</lpage><pub-id pub-id-type="doi">10.1097/CM9.0000000000001966</pub-id><pub-id pub-id-type="pmid">35089886</pub-id>
</element-citation>
      </ref>
      <ref id="CR64">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name></person-group><article-title>Increased diagnostic yield in a cohort of hearing loss families using a comprehensive stepwise strategy of molecular testing</article-title><source>Front Genet</source><year>2022</year><volume>13</volume><fpage>1057293</fpage><pub-id pub-id-type="doi">10.3389/fgene.2022.1057293</pub-id><pub-id pub-id-type="pmid">36568381</pub-id>
</element-citation>
      </ref>
      <ref id="CR65">
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Quan</surname><given-names>R</given-names></name><name><surname>Xia</surname><given-names>EJ</given-names></name><name><surname>Bhandari</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>Original tumour suppressor gene polycystic kidney and hepatic disease 1-like 1 is associated with thyroid cancer cell progression</article-title><source>Oncol Lett</source><year>2019</year><volume>18</volume><fpage>3227</fpage><lpage>3235</lpage><pub-id pub-id-type="doi">10.3892/ol.2019.10632</pub-id><pub-id pub-id-type="pmid">31452800</pub-id>
</element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>